<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:08:59Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8046191" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8046191</identifier>
        <datestamp>2021-04-21</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8046191</article-id>
              <article-id pub-id-type="pmcid">PMC8046191</article-id>
              <article-id pub-id-type="pmc-uid">8046191</article-id>
              <article-id pub-id-type="pmid">33852611</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0249524</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-20-40256</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Cardiology</subject>
                    <subj-group>
                      <subject>Arrhythmia</subject>
                      <subj-group>
                        <subject>Atrial Fibrillation</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Clinical Medicine</subject>
                    <subj-group>
                      <subject>Signs and Symptoms</subject>
                      <subj-group>
                        <subject>Hemorrhage</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Vascular Medicine</subject>
                    <subj-group>
                      <subject>Hemorrhage</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pharmaceutics</subject>
                    <subj-group>
                      <subject>Drug Therapy</subject>
                      <subj-group>
                        <subject>Antiplatelet Therapy</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pharmaceutics</subject>
                    <subj-group>
                      <subject>Drug Therapy</subject>
                      <subj-group>
                        <subject>Cardiovascular Therapy</subject>
                        <subj-group>
                          <subject>Anticoagulant Therapy</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Cardiovascular Diseases</subject>
                      <subj-group>
                        <subject>Cardiovascular Disease Risk</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Cardiology</subject>
                    <subj-group>
                      <subject>Cardiovascular Medicine</subject>
                      <subj-group>
                        <subject>Cardiovascular Diseases</subject>
                        <subj-group>
                          <subject>Cardiovascular Disease Risk</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>People and Places</subject>
                  <subj-group>
                    <subject>Geographical Locations</subject>
                    <subj-group>
                      <subject>Asia</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Cerebrovascular Diseases</subject>
                      <subj-group>
                        <subject>Stroke</subject>
                        <subj-group>
                          <subject>Ischemic Stroke</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Neurology</subject>
                    <subj-group>
                      <subject>Cerebrovascular Diseases</subject>
                      <subj-group>
                        <subject>Stroke</subject>
                        <subj-group>
                          <subject>Ischemic Stroke</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Vascular Medicine</subject>
                    <subj-group>
                      <subject>Stroke</subject>
                      <subj-group>
                        <subject>Ischemic Stroke</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pulmonology</subject>
                    <subj-group>
                      <subject>Chronic Obstructive Pulmonary Disease</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF</article-title>
                <alt-title alt-title-type="running-head">Multimorbidity in GLORIA-AF</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0384-1975</contrib-id>
                  <name>
                    <surname>Kozieł</surname>
                    <given-names>Monika</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Teutsch</surname>
                    <given-names>Christine</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Halperin</surname>
                    <given-names>Jonathan L.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rothman</surname>
                    <given-names>Kenneth J.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Diener</surname>
                    <given-names>Hans-Christoph</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ma</surname>
                    <given-names>Chang-Sheng</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff007">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Marler</surname>
                    <given-names>Sabrina</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff008">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lu</surname>
                    <given-names>Shihai</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Software</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff008">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gurusamy</surname>
                    <given-names>Venkatesh K.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Resources</role>
                  <role content-type="https://casrai.org/credit/">Software</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff009">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Huisman</surname>
                    <given-names>Menno V.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff010">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lip</surname>
                    <given-names>Gregory Y. H.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Validation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff011">
                    <sup>11</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <collab>on behalf of the GLORIA-AF Investigators</collab>
                  <xref ref-type="author-notes" rid="fn001">
                    <sup>¶</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart &amp; Chest Hospital, Liverpool, United Kingdom</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>1st Department of Cardiology and Angiology, Silesian Centre for Heart Diseases, Zabrze, Poland</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Department of Clinical Development and Medical Affairs, Therapeutic Area Cardiometabolism, Boehringer Ingelheim International GmbH, Ingelheim, Germany</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Icahn School of Medicine at Mount Sinai, New York, New York, United States of America</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>RTI Health Solutions, Research Triangle Park, North Carolina, United States of America</addr-line>
              </aff>
              <aff id="aff006">
                <label>6</label>
                <addr-line>Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany</addr-line>
              </aff>
              <aff id="aff007">
                <label>7</label>
                <addr-line>Cardiology Department, Atrial Fibrillation Center, Beijing AnZhen Hospital, Capital Medical University, Beijing, China</addr-line>
              </aff>
              <aff id="aff008">
                <label>8</label>
                <addr-line>Biostatistics and Data Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, United States of America</addr-line>
              </aff>
              <aff id="aff009">
                <label>9</label>
                <addr-line>Global Epidemiology, Boehringer Ingelheim International GmbH, Ingelheim, Germany</addr-line>
              </aff>
              <aff id="aff010">
                <label>10</label>
                <addr-line>Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands</addr-line>
              </aff>
              <aff id="aff011">
                <label>11</label>
                <addr-line>Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Garcia de Frutos</surname>
                    <given-names>Pablo</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Institut d’Investigacions Biomediques de Barcelona, SPAIN</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The authors have read the journal’s policy and have the following competing interests: Dr. Teutsch, Sabrina Marler, and Venkatesh K. Gurusamy are paid employees of Boehringer Ingelheim. Dr. Lu was a paid employee of Boehringer Ingelheim at the time that the manuscript was written. Professor Halperin has engaged in consulting activities for Boehringer Ingelheim and advisory activities involving anticoagulants, and he is a member of the Executive Steering Committee of the GLORIA-AF Registry. Over the past 3 years, Professor Diener received honoraria for participation in clinical trials, contribution to advisory boards, or oral presentations from: Abbott, Bayer Vital, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Pfizer, Portola, Sanofi-Aventis, and WebMD Global. Financial support for research projects was provided by Boehringer Ingelheim. He received research grants from the German Research Council (DFG), German Ministry of Education and Research (BMBF), European Union, NIH, Bertelsmann Foundation, and Heinz-Nixdorf Foundation. Professor Ma received honoraria from Bristol-Myers Squibb, Pfizer, Johnson &amp; Johnson, Boehringer Ingelheim, Bayer, and AstraZeneca for giving lectures. Professor Huisman reports grants from ZonMW Dutch Healthcare Fund, grants and personal fees from Boehringer Ingelheim, Pfizer/Bristol-Myers Squibb, Bayer Health Care, Aspen, Daiichi Sankyo, outside the submitted work. Professor Lip has been a consultant for Bayer/Janssen, Bristol-Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi Sankyo. He has been a speaker for Bayer, Bristol-Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi Sankyo. No fees directly received personally. These competing interests do not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare. Dr Kozieł and Professor Rothman declare no competing interests.</p>
                </fn>
                <fn fn-type="other" id="fn001">
                  <p>¶ Membership of the GLORIA-AF Investigators Group is listed in the Acknowledgments.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>gregory.lip@liverpool.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>14</day>
                <month>4</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2021</year>
              </pub-date>
              <volume>16</volume>
              <issue>4</issue>
              <elocation-id>e0249524</elocation-id>
              <history>
                <date date-type="received">
                  <day>23</day>
                  <month>12</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>21</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 Kozieł et al</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Kozieł et al</copyright-holder>
                <license>
                  <ali:license_ref specific-use="pmc" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0249524.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Background</title>
                  <p>Patients with AF often have multimorbidity (the presence of ≥2 concomitant chronic conditions).</p>
                </sec>
                <sec id="sec002">
                  <title>Objective</title>
                  <p>To describe baseline characteristics, patterns of antithrombotic therapy, and factors associated with oral anticoagulant (OAC) prescription in patients with AF and ≥2 concomitant, chronic, comorbid conditions.</p>
                </sec>
                <sec id="sec003">
                  <title>Methods</title>
                  <p>Phase III of the GLORIA-AF Registry enrolled consecutive patients from January 2014 through December 2016 with recently diagnosed AF and CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥1 to assess the safety and effectiveness of antithrombotic treatment.</p>
                </sec>
                <sec id="sec004">
                  <title>Results</title>
                  <p>Of 21,241 eligible patients, 15,119 (71.2%) had ≥2 concomitant, chronic, comorbid conditions. The proportions of patients with multimorbidity receiving non-vitamin K antagonist oral anticoagulants (NOACs) and vitamin K antagonists (VKA) were 60.2% and 23.6%, respectively. The proportion with paroxysmal AF was 57.0% in the NOAC group and 45.4% in the VKA group. Multivariable log-binomial regression analysis found the following factors were associated with no OAC prescription: pattern of AF (paroxysmal, persistent, or permanent), coronary artery disease, myocardial infarction, prior bleeding, smoking status, and region (Asia, North America, or Europe). Factors associated with OAC prescriptions were age, body mass index, renal function, hypertension, history of cerebral ischemic symptoms, and AF ablation.</p>
                </sec>
                <sec id="sec005">
                  <title>Conclusion</title>
                  <p>Multimorbid AF patients prescribed NOACs have fewer comorbidities than those prescribed VKAs. Age, AF pattern, comorbidities, and renal function are associated with OAC prescription.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100008349</institution-id>
                      <institution>Boehringer Ingelheim</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <funding-statement>The work was supported by Boehringer Ingelheim, Germany. The funder provided support in the form of salaries for authors [CT, SL, SM, VKG, JH, CD, CM, MH, GYHL], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="0"/>
                <table-count count="5"/>
                <page-count count="34"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the manuscript and its <xref ref-type="sec" rid="sec022">Supporting information</xref> files.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the manuscript and its <xref ref-type="sec" rid="sec022">Supporting information</xref> files.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec006">
              <title>Introduction</title>
              <p>Atrial fibrillation (AF) affects approximately 3% of adults and its prevalence and incidence are rising [<xref rid="pone.0249524.ref001" ref-type="bibr">1</xref>] with the aging of the population [<xref rid="pone.0249524.ref002" ref-type="bibr">2</xref>]. Older patients with AF often have other chronic conditions that affect their clinical course [<xref rid="pone.0249524.ref003" ref-type="bibr">3</xref>]. Multimorbidity (the presence of ≥2 concomitant chronic conditions) demands a holistic and integrated approach to patient care [<xref rid="pone.0249524.ref004" ref-type="bibr">4</xref>] since these patients face higher risks of stroke and bleeding than those without comorbidities [<xref rid="pone.0249524.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0249524.ref006" ref-type="bibr">6</xref>]. The interplay between comorbidity, AF, and optimal thromboprophylaxis has both medical and economic implications [<xref rid="pone.0249524.ref007" ref-type="bibr">7</xref>]</p>
              <p>The aim of this analysis of the GLORIA-AF dataset is to describe baseline characteristics and antithrombotic therapy prescription patterns in patients with AF and multimorbidity and to identify factors associated with the selection of an oral anticoagulant (OAC) type for these complex patients.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec007">
              <title>Materials and methods</title>
              <p>The design of the GLORIA-AF registry (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/home">https://clinicaltrials.gov/ct2/home</ext-link>; trial registration numbers NCT01468701, NCT01671007, NCT01937377) has been reported [<xref rid="pone.0249524.ref008" ref-type="bibr">8</xref>]. The study protocol is concordant with the ethical guidelines of the 1975 Declaration of Helsinki, and informed consent was obtained from each patient before enrollment.</p>
              <p>The registry collected routine clinical practice data regarding patients with newly diagnosed AF to evaluate patient characteristics influencing the selection, safety, and effectiveness of antithrombotic therapy. Phase I was conducted before non-vitamin K antagonist oral anticoagulants (NOACs) were available for stroke prevention in AF. Phase II began when dabigatran was approved in countries with participating clinical centers. Baseline characteristics were collected and those prescribed dabigatran were followed up for 2 years in Phase II. Phase III, which started when dabigatran had been more widely adopted, gathered data for up to 3 years, regardless of antithrombotic management [<xref rid="pone.0249524.ref008" ref-type="bibr">8</xref>].</p>
              <p>Consecutive patients from 38 countries were enrolled between 2014 and 2016. Adult patients with recently diagnosed nonvalvular AF (&lt;3 months before the baseline visit; Latin America &lt;4.5 months) at risk of stroke (CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥1) achieved by any of the following: heart failure or left ventricular systolic dysfunction, hypertension, diabetes, prior stroke, transient ischemic attack (TIA) or systemic embolism, myocardial infarction (MI), peripheral artery disease, age ≥65 years, or female sex, were enrolled [<xref rid="pone.0249524.ref009" ref-type="bibr">9</xref>]. The risks of stroke and bleeding were assessed using the CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED (1 point is achieved by any of the following: hypertension, abnormal renal or hepatic function, prior stroke, bleeding or predisposition, labile International Normalised Ratio, elderly [&gt;65 years], or concomitant use of alcohol or anti-inflammatory medications) [<xref rid="pone.0249524.ref010" ref-type="bibr">10</xref>]. Antithrombotic therapy was prescribed by the treating physicians according to local standards. This report is focused on baseline data obtained from patients in Phase III, collected using electronic case report forms.</p>
              <sec id="sec008">
                <title>Statistical analysis</title>
                <p>Baseline characteristics are summarized descriptively. Categorical variables are reported as absolute frequencies and percentages, and continuous variables are summarized by median (Quartile 1, Quartile 3). Baseline characteristics included stratification of patients with AF and multimorbidity according to stroke prevention strategies (OAC vs antiplatelet vs no antithrombotic therapy, NOAC vs vitamin K antagonists [VKAs], and NOACs once daily [QD] vs twice daily [BID]). Standardized differences were used to compare baseline characteristics across various stroke prevention strategies, focusing on variables with the highest standardized differences; differences ≤10% in absolute value were considered as balanced between groups [<xref rid="pone.0249524.ref011" ref-type="bibr">11</xref>].</p>
                <p>Factors associated with antithrombotic treatment choice were analyzed by log-binomial, multivariable regression models, providing relative probability ratios for prescription (OAC vs no OAC use, NOAC vs VKA; and by region). Missing data were handled using multiple imputation, replacing missing data with multiple simulated values based on regression models to provide comparatively unbiased estimates under the missing-at-random assumption. The procedure introduces random error to compensate for the added, imputed information. The imputation regression models used 56 predictors to impute the missing data, and were repeated 20 times to give 20 datasets with imputed data [<xref rid="pone.0249524.ref012" ref-type="bibr">12</xref>].</p>
                <p>Confidence intervals were calculated based on likelihood ratios and Rubin’s method to combine results across imputations. Both univariate and multivariable log-binomial regression analyses were performed to evaluate crude as well as the adjusted probability ratios together with 95% confidence intervals. The term “probability ratio” was used rather than “risk ratio”, as our measure describes treatment selections rather than adverse outcomes.</p>
                <p>All data were calculated using SAS version 9.4 (SAS Institute, Inc., Cary, NC).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec009">
              <title>Results</title>
              <p>Of 21,241 eligible patients in this subanalysis, 15,119 (71.2%) had ≥2 concomitant, chronic conditions (<xref rid="pone.0249524.t001" ref-type="table">Table 1</xref>).</p>
              <table-wrap id="pone.0249524.t001" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0249524.t001</object-id>
                <label>Table 1</label>
                <caption>
                  <title>Proportion of AF patients according to number of comorbid diseases<xref ref-type="table-fn" rid="t001fn001"><sup>a</sup></xref>.</title>
                </caption>
                <alternatives>
                  <graphic id="pone.0249524.t001g" xlink:href="pone.0249524.t001"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Number of Comorbid Diseases</th>
                        <th align="center" rowspan="1" colspan="1">Number of Patients (n = 21,241)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">0</td>
                        <td align="center" rowspan="1" colspan="1">1434 (6.8)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">1</td>
                        <td align="center" rowspan="1" colspan="1">4688 (22.1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="center" rowspan="1" colspan="1">5559 (26.2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="center" rowspan="1" colspan="1">4286 (20.2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="center" rowspan="1" colspan="1">2664 (12.5)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">5</td>
                        <td align="center" rowspan="1" colspan="1">1463 (6.9)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">6</td>
                        <td align="center" rowspan="1" colspan="1">695 (3.3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">7</td>
                        <td align="center" rowspan="1" colspan="1">332 (1.6)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">8</td>
                        <td align="center" rowspan="1" colspan="1">88 (0.4)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">9</td>
                        <td align="center" rowspan="1" colspan="1">22 (0.1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">10</td>
                        <td align="center" rowspan="1" colspan="1">8 (0.0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">11</td>
                        <td align="center" rowspan="1" colspan="1">2 (0.0)</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t001fn001">
                    <p><sup>a</sup>AF = atrial fibrillation.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <sec id="sec010">
                <title>Baseline characteristics of AF multimorbid patients</title>
                <p>Baseline characteristics of patients are summarized based on antithrombotic therapy (<xref rid="pone.0249524.t002" ref-type="table">Table 2</xref>). Among multimorbid AF patients, 83.8% were prescribed OACs, 11.0% were prescribed antiplatelet therapy, and 5.2% were prescribed no antithrombotic therapy. The median (66.0, 79.0) age was 73.0 years in the OAC group, 71.0 (63.0–79.0) years in the antiplatelet therapy group, and 72.0 (64.0–80.0) years in the no antithrombotic therapy group. The proportions of females in these groups were 44.5%, 41.7%, and 45.5%, respectively. The median CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED scores were similar across the 3 groups.</p>
                <table-wrap id="pone.0249524.t002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0249524.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Baseline characteristics of AF multimorbid patients prescribed OAC or antiplatelets or no antithrombotic therapy<xref ref-type="table-fn" rid="t002fn001"><sup>a</sup></xref>.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0249524.t002g" xlink:href="pone.0249524.t002"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="center" rowspan="1" colspan="1">OAC (n = 12,677)</th>
                          <th align="center" rowspan="1" colspan="1">Antiplatelets (n = 1658)</th>
                          <th align="center" rowspan="1" colspan="1">No Antithrombotic Therapy (n = 784)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Age (y), median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">73.0 (66.0–79.0)</td>
                          <td align="center" rowspan="1" colspan="1">71.0 (63.0–79.0)</td>
                          <td align="center" rowspan="1" colspan="1">72.0 (64.0–80.0)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Females, n (%)</td>
                          <td align="center" rowspan="1" colspan="1">5645 (44.5)</td>
                          <td align="center" rowspan="1" colspan="1">691 (41.7)</td>
                          <td align="center" rowspan="1" colspan="1">357 (45.5)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">28.0 (24.8–32.0)</td>
                          <td align="center" rowspan="1" colspan="1">26.1 (23.5–30.0)</td>
                          <td align="center" rowspan="1" colspan="1">26.1 (23.4–29.6)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Missing</td>
                          <td align="center" rowspan="1" colspan="1">123 (1.0)</td>
                          <td align="center" rowspan="1" colspan="1">17 (1.0)</td>
                          <td align="center" rowspan="1" colspan="1">8 (1.0)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Current smoker</td>
                          <td align="center" rowspan="1" colspan="1">1145 (9.0)</td>
                          <td align="center" rowspan="1" colspan="1">223 (13.4)</td>
                          <td align="center" rowspan="1" colspan="1">100 (12.8)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Alcohol abuse, ≥8 units/ week</td>
                          <td align="center" rowspan="1" colspan="1">866 (6.8)</td>
                          <td align="center" rowspan="1" colspan="1">85 (5.1)</td>
                          <td align="center" rowspan="1" colspan="1">54 (6.9)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Type of AF, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Paroxysmal</td>
                          <td align="center" rowspan="1" colspan="1">6810 (53.7)</td>
                          <td align="center" rowspan="1" colspan="1">1166 (70.3)</td>
                          <td align="center" rowspan="1" colspan="1">496 (63.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Persistent</td>
                          <td align="center" rowspan="1" colspan="1">4478 (35.3)</td>
                          <td align="center" rowspan="1" colspan="1">401 (24.2)</td>
                          <td align="center" rowspan="1" colspan="1">242 (30.9)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Permanent</td>
                          <td align="center" rowspan="1" colspan="1">1389 (11.0)</td>
                          <td align="center" rowspan="1" colspan="1">91 (5.5)</td>
                          <td align="center" rowspan="1" colspan="1">46 (5.9)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Categorization of AF, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> EHRA I</td>
                          <td align="center" rowspan="1" colspan="1">4686 (37.0)</td>
                          <td align="center" rowspan="1" colspan="1">550 (33.2)</td>
                          <td align="center" rowspan="1" colspan="1">273 (34.8)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> EHRA II</td>
                          <td align="center" rowspan="1" colspan="1">4025 (31.8)</td>
                          <td align="center" rowspan="1" colspan="1">563 (34.0)</td>
                          <td align="center" rowspan="1" colspan="1">270 (34.4)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> EHRA III</td>
                          <td align="center" rowspan="1" colspan="1">3063 (24.2)</td>
                          <td align="center" rowspan="1" colspan="1">431 (26.0)</td>
                          <td align="center" rowspan="1" colspan="1">183 (23.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> EHRA IV</td>
                          <td align="center" rowspan="1" colspan="1">903 (7.1)</td>
                          <td align="center" rowspan="1" colspan="1">114 (6.9)</td>
                          <td align="center" rowspan="1" colspan="1">58 (7.4)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Creatinine clearance (mL/min) (measured), median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">70.6 (52.5–95.3)</td>
                          <td align="center" rowspan="1" colspan="1">69.5 (50.9–92.4)</td>
                          <td align="center" rowspan="1" colspan="1">67.8 (49.7–90.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Creatinine clearance (mL/min), n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> &lt;15</td>
                          <td align="center" rowspan="1" colspan="1">100 (0.8)</td>
                          <td align="center" rowspan="1" colspan="1">18 (1.1)</td>
                          <td align="center" rowspan="1" colspan="1">10 (1.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 15–29</td>
                          <td align="center" rowspan="1" colspan="1">305 (2.4)</td>
                          <td align="center" rowspan="1" colspan="1">62 (3.7)</td>
                          <td align="center" rowspan="1" colspan="1">23 (2.9)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 30–49</td>
                          <td align="center" rowspan="1" colspan="1">1848 (14.6)</td>
                          <td align="center" rowspan="1" colspan="1">252 (15.2)</td>
                          <td align="center" rowspan="1" colspan="1">136 (17.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 50–79</td>
                          <td align="center" rowspan="1" colspan="1">4152 (32.8)</td>
                          <td align="center" rowspan="1" colspan="1">526 (31.7)</td>
                          <td align="center" rowspan="1" colspan="1">253 (32.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> ≥80</td>
                          <td align="center" rowspan="1" colspan="1">4080 (32.2)</td>
                          <td align="center" rowspan="1" colspan="1">520 (31.4)</td>
                          <td align="center" rowspan="1" colspan="1">243 (31.0)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Missing</td>
                          <td align="center" rowspan="1" colspan="1">2192 (17.3)</td>
                          <td align="center" rowspan="1" colspan="1">280 (16.9)</td>
                          <td align="center" rowspan="1" colspan="1">119 (15.2)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc score, median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">4.0 (3.0–5.0)</td>
                          <td align="center" rowspan="1" colspan="1">4.0 (2.0–5.0)</td>
                          <td align="center" rowspan="1" colspan="1">3.0 (2.0–4.0)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">HAS-BLED score, median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (1.0–2.0)</td>
                          <td align="center" rowspan="1" colspan="1">2.0 (2.0–3.0)</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (1.0–2.0)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Missing (HAS-BLED), n (%)</td>
                          <td align="center" rowspan="1" colspan="1">1234 (9.7)</td>
                          <td align="center" rowspan="1" colspan="1">134 (8.1)</td>
                          <td align="center" rowspan="1" colspan="1">69 (8.8)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Medical history, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Congestive heart failure</td>
                          <td align="center" rowspan="1" colspan="1">3509 (27.7)</td>
                          <td align="center" rowspan="1" colspan="1">487 (29.4)</td>
                          <td align="center" rowspan="1" colspan="1">215 (27.4)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Hypertension</td>
                          <td align="center" rowspan="1" colspan="1">10,989 (86.7)</td>
                          <td align="center" rowspan="1" colspan="1">1370 (82.6)</td>
                          <td align="center" rowspan="1" colspan="1">638 (81.4)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Diabetes mellitus</td>
                          <td align="center" rowspan="1" colspan="1">4021 (31.7)</td>
                          <td align="center" rowspan="1" colspan="1">510 (30.8)</td>
                          <td align="center" rowspan="1" colspan="1">226 (28.8)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Previous stroke or TIA</td>
                          <td align="center" rowspan="1" colspan="1">2347 (18.5)</td>
                          <td align="center" rowspan="1" colspan="1">336 (20.3)</td>
                          <td align="center" rowspan="1" colspan="1">159 (20.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Myocardial infarction</td>
                          <td align="center" rowspan="1" colspan="1">1580 (12.5)</td>
                          <td align="center" rowspan="1" colspan="1">384 (23.2)</td>
                          <td align="center" rowspan="1" colspan="1">58 (7.4)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Coronary artery disease</td>
                          <td align="center" rowspan="1" colspan="1">3017 (23.8)</td>
                          <td align="center" rowspan="1" colspan="1">745 (44.9)</td>
                          <td align="center" rowspan="1" colspan="1">149 (19.0)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Peripheral artery disease</td>
                          <td align="center" rowspan="1" colspan="1">503 (4.0)</td>
                          <td align="center" rowspan="1" colspan="1">79 (4.8)</td>
                          <td align="center" rowspan="1" colspan="1">21 (2.7)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Cancer</td>
                          <td align="center" rowspan="1" colspan="1">1671 (13.2)</td>
                          <td align="center" rowspan="1" colspan="1">167 (10.1)</td>
                          <td align="center" rowspan="1" colspan="1">115 (14.7)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Dementia</td>
                          <td align="center" rowspan="1" colspan="1">101 (0.8)</td>
                          <td align="center" rowspan="1" colspan="1">18 (1.1)</td>
                          <td align="center" rowspan="1" colspan="1">1 (0.1)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Gastric ulcer</td>
                          <td align="center" rowspan="1" colspan="1">145 (1.1)</td>
                          <td align="center" rowspan="1" colspan="1">20 (1.2)</td>
                          <td align="center" rowspan="1" colspan="1">13 (1.7)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Gastritis or duodenitis</td>
                          <td align="center" rowspan="1" colspan="1">455 (3.6)</td>
                          <td align="center" rowspan="1" colspan="1">70 (4.2)</td>
                          <td align="center" rowspan="1" colspan="1">50 (6.4)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Chronic kidney disease</td>
                          <td align="center" rowspan="1" colspan="1">3881 (30.6)</td>
                          <td align="center" rowspan="1" colspan="1">526 (31.7)</td>
                          <td align="center" rowspan="1" colspan="1">271 (34.6)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> COPD</td>
                          <td align="center" rowspan="1" colspan="1">1045 (8.2)</td>
                          <td align="center" rowspan="1" colspan="1">120 (7.2)</td>
                          <td align="center" rowspan="1" colspan="1">59 (7.5)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Bleeding (after diagnosis of AF), n (%)</td>
                          <td align="center" rowspan="1" colspan="1">182 (1.4)</td>
                          <td align="center" rowspan="1" colspan="1">32 (1.9)</td>
                          <td align="center" rowspan="1" colspan="1">33 (4.2)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Bleeding on OAC, n (%)</td>
                          <td align="center" rowspan="1" colspan="1">159 (87.4)</td>
                          <td align="center" rowspan="1" colspan="1">27 (84.4)</td>
                          <td align="center" rowspan="1" colspan="1">18 (54.5)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Location of bleeding (after diagnosis of AF), n (%)<xref ref-type="table-fn" rid="t002fn002">*</xref></td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Intracranial hemorrhage</td>
                          <td align="center" rowspan="1" colspan="1">12 (6.6)</td>
                          <td align="center" rowspan="1" colspan="1">6 (18.8)</td>
                          <td align="center" rowspan="1" colspan="1">8 (24.2)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Upper GI bleed</td>
                          <td align="center" rowspan="1" colspan="1">12 (6.6)</td>
                          <td align="center" rowspan="1" colspan="1">4 (12.5)</td>
                          <td align="center" rowspan="1" colspan="1">3 (9.1)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Lower GI bleed</td>
                          <td align="center" rowspan="1" colspan="1">25 (13.7)</td>
                          <td align="center" rowspan="1" colspan="1">6 (18.8)</td>
                          <td align="center" rowspan="1" colspan="1">5 (15.2)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> GI bleed not further specified</td>
                          <td align="center" rowspan="1" colspan="1">11 (6.0)</td>
                          <td align="center" rowspan="1" colspan="1">4 (12.5)</td>
                          <td align="center" rowspan="1" colspan="1">4 (12.1)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Urogenital hemorrhage</td>
                          <td align="center" rowspan="1" colspan="1">31 (17.0)</td>
                          <td align="center" rowspan="1" colspan="1">3 (9.4)</td>
                          <td align="center" rowspan="1" colspan="1">3 (9.1)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Bleeding at other location</td>
                          <td align="center" rowspan="1" colspan="1">81 (44.5)</td>
                          <td align="center" rowspan="1" colspan="1">7 (21.9)</td>
                          <td align="center" rowspan="1" colspan="1">8 (24.2)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Bleeding with unknown location</td>
                          <td align="center" rowspan="1" colspan="1">10 (5.5)</td>
                          <td align="center" rowspan="1" colspan="1">2 (6.3)</td>
                          <td align="center" rowspan="1" colspan="1">2 (6.1)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Region, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Asia</td>
                          <td align="center" rowspan="1" colspan="1">1739 (13.7)</td>
                          <td align="center" rowspan="1" colspan="1">719 (43.4)</td>
                          <td align="center" rowspan="1" colspan="1">325 (41.5)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Europe</td>
                          <td align="center" rowspan="1" colspan="1">6514 (51.4)</td>
                          <td align="center" rowspan="1" colspan="1">443 (26.7)</td>
                          <td align="center" rowspan="1" colspan="1">266 (33.9)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> North America</td>
                          <td align="center" rowspan="1" colspan="1">3429 (27.0)</td>
                          <td align="center" rowspan="1" colspan="1">415 (25.0)</td>
                          <td align="center" rowspan="1" colspan="1">144 (18.4)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Latin America</td>
                          <td align="center" rowspan="1" colspan="1">995 (7.8)</td>
                          <td align="center" rowspan="1" colspan="1">81 (4.9)</td>
                          <td align="center" rowspan="1" colspan="1">49 (6.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Type of site, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> GP/primary care</td>
                          <td align="center" rowspan="1" colspan="1">686 (5.4)</td>
                          <td align="center" rowspan="1" colspan="1">171 (10.3)</td>
                          <td align="center" rowspan="1" colspan="1">77 (9.8)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Specialist office</td>
                          <td align="center" rowspan="1" colspan="1">3902 (30.8)</td>
                          <td align="center" rowspan="1" colspan="1">512 (30.9)</td>
                          <td align="center" rowspan="1" colspan="1">191 (24.4)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Community hospital</td>
                          <td align="center" rowspan="1" colspan="1">3757 (29.6)</td>
                          <td align="center" rowspan="1" colspan="1">350 (21.1)</td>
                          <td align="center" rowspan="1" colspan="1">175 (22.3)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> University hospital</td>
                          <td align="center" rowspan="1" colspan="1">3878 (30.6)</td>
                          <td align="center" rowspan="1" colspan="1">543 (32.8)</td>
                          <td align="center" rowspan="1" colspan="1">326 (41.6)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Outpatient health care centre</td>
                          <td align="center" rowspan="1" colspan="1">222 (1.8)</td>
                          <td align="center" rowspan="1" colspan="1">51 (3.1)</td>
                          <td align="center" rowspan="1" colspan="1">6 (0.8)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Anticoagulation clinics</td>
                          <td align="center" rowspan="1" colspan="1">82 (0.6)</td>
                          <td align="center" rowspan="1" colspan="1">6 (0.4)</td>
                          <td align="center" rowspan="1" colspan="1">4 (0.5)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Other</td>
                          <td align="center" rowspan="1" colspan="1">150 (1.2)</td>
                          <td align="center" rowspan="1" colspan="1">25 (1.5)</td>
                          <td align="center" rowspan="1" colspan="1">5 (0.6)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t002fn001">
                      <p><sup>a</sup>AF = atrial fibrillation; BMI = body mass index; CHA<sub>2</sub>DS<sub>2</sub>-VASc = congestive heart failure/left ventricular dysfunction, hypertension, age ≥75 years, diabetes, stroke/transient ischemic attack/systemic embolism, vascular disease, age 65–74 years, sex category (female); COPD = chronic obstructive pulmonary disease; EHRA = European Heart Rhythm Association; GI = gastrointestinal; GP = general practitioner; HAS-BLED = hypertension, abnormal renal /liver function, stroke, bleeding history or predisposition, labile International Normalised Ratio, elderly (&gt;65 years), drugs or alcohol concomitantly; OAC = oral anticoagulant; Q = quartile; TIA = transient ischemic attack; y = years.</p>
                    </fn>
                    <fn id="t002fn002">
                      <p>*Proportion calculated out of Bleeding (after diagnosis of AF).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Baseline characteristics of patients prescribed NOACs or VKAs are shown in <xref rid="pone.0249524.t003" ref-type="table">Table 3</xref>. The median age was 73.0 (66.0–79.0) years, and the proportion of females was 44% in both treatment groups. There were no differences in CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED scores between these 2 groups. The prevalence of paroxysmal AF in patients with multimorbidity on NOACs and VKAs was 57.0% and 45.4%, respectively. Among patients on NOACs, 38.4% had a European Heart Rhythm Association symptom score of I, compared with 33.3% for patients on VKAs. A lower proportion (1.6%) of patients on NOACs had a glomerular filtration rate of 15–29 mL/min, compared with 4.4% of those on VKAs.</p>
                <table-wrap id="pone.0249524.t003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0249524.t003</object-id>
                  <label>Table 3</label>
                  <caption>
                    <title>Baseline characteristics of AF multimorbid patients prescribed NOACs or VKAs<xref ref-type="table-fn" rid="t003fn001"><sup>a</sup></xref>.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0249524.t003g" xlink:href="pone.0249524.t003"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="center" rowspan="1" colspan="1">NOAC (n = 9105)</th>
                          <th align="center" rowspan="1" colspan="1">VKA (n = 3572)</th>
                          <th align="center" rowspan="1" colspan="1">Standardized Difference</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Age (y), median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">73.0 (66.0–79.0)</td>
                          <td align="center" rowspan="1" colspan="1">73.0 (66.0–79.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.005</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Females, n (%)</td>
                          <td align="center" rowspan="1" colspan="1">4072 (44.7)</td>
                          <td align="center" rowspan="1" colspan="1">1573 (44.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.014</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2)</sup>, median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">28.0 (24.8–32.2)</td>
                          <td align="center" rowspan="1" colspan="1">27.8 (24.6–31.6)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.066</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Missing</td>
                          <td align="center" rowspan="1" colspan="1">37 (1.2)</td>
                          <td align="center" rowspan="1" colspan="1">60 (1.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.020</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Current smoker</td>
                          <td align="center" rowspan="1" colspan="1">812 (8.9)</td>
                          <td align="center" rowspan="1" colspan="1">333 (9.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.014</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Alcohol abuse, ≥8 units/ week</td>
                          <td align="center" rowspan="1" colspan="1">651 (7.1)</td>
                          <td align="center" rowspan="1" colspan="1">215 (6.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.046</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Type of AF, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Paroxysmal</td>
                          <td align="center" rowspan="1" colspan="1">5187 (57.0)</td>
                          <td align="center" rowspan="1" colspan="1">1623 (45.4)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.232</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Persistent</td>
                          <td align="center" rowspan="1" colspan="1">3052 (33.5)</td>
                          <td align="center" rowspan="1" colspan="1">1426 (39.9)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.133</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Permanent</td>
                          <td align="center" rowspan="1" colspan="1">866 (9.5)</td>
                          <td align="center" rowspan="1" colspan="1">523 (14.6)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.158</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Categorization of AF, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> EHRA I</td>
                          <td align="center" rowspan="1" colspan="1">3496 (38.4)</td>
                          <td align="center" rowspan="1" colspan="1">1190 (33.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.106</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> EHRA II</td>
                          <td align="center" rowspan="1" colspan="1">2886 (31.7)</td>
                          <td align="center" rowspan="1" colspan="1">1139 (31.9)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.004</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> EHRA III</td>
                          <td align="center" rowspan="1" colspan="1">2131 (23.4)</td>
                          <td align="center" rowspan="1" colspan="1">932 (26.1)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.062</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> EHRA IV</td>
                          <td align="center" rowspan="1" colspan="1">592 (6.5)</td>
                          <td align="center" rowspan="1" colspan="1">311 (8.7)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.083</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Creatinine clearance (mL/min) (measured), median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">72.1 (53.7–97.0)</td>
                          <td align="center" rowspan="1" colspan="1">66.8 (48.9–91.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.078</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Creatinine clearance (mL/min) n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> &lt;15</td>
                          <td align="center" rowspan="1" colspan="1">50 (0.5)</td>
                          <td align="center" rowspan="1" colspan="1">50 (1.4)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.087</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 15–29</td>
                          <td align="center" rowspan="1" colspan="1">148 (1.6)</td>
                          <td align="center" rowspan="1" colspan="1">157 (4.4)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.163</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 30–49</td>
                          <td align="center" rowspan="1" colspan="1">1280 (14.1)</td>
                          <td align="center" rowspan="1" colspan="1">568 (15.9)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.052</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 50–79</td>
                          <td align="center" rowspan="1" colspan="1">3046 (33.5)</td>
                          <td align="center" rowspan="1" colspan="1">1106 (31.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.053</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> ≥80</td>
                          <td align="center" rowspan="1" colspan="1">3053 (33.5)</td>
                          <td align="center" rowspan="1" colspan="1">1027 (28.8)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.103</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Missing</td>
                          <td align="center" rowspan="1" colspan="1">1528 (16.8)</td>
                          <td align="center" rowspan="1" colspan="1">664 (18.6)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.047</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc score, median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">4.0 (3.0–5.0)</td>
                          <td align="center" rowspan="1" colspan="1">4.0 (3.0–5.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.080</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">HAS-BLED score, median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (1.0–2.0)</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (1.0–2.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.016</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Missing (HAS-BLED), n (%)</td>
                          <td align="center" rowspan="1" colspan="1">858 (9.4)</td>
                          <td align="center" rowspan="1" colspan="1">376 (10.5)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.037</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Medical history, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Congestive heart failure</td>
                          <td align="center" rowspan="1" colspan="1">2232 (24.5)</td>
                          <td align="center" rowspan="1" colspan="1">1277 (35.8)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.247</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Hypertension</td>
                          <td align="center" rowspan="1" colspan="1">7907 (86.8)</td>
                          <td align="center" rowspan="1" colspan="1">3082 (86.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.016</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Diabetes mellitus</td>
                          <td align="center" rowspan="1" colspan="1">2839 (31.2)</td>
                          <td align="center" rowspan="1" colspan="1">1182 (33.1)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.041</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Previous stroke or TIA</td>
                          <td align="center" rowspan="1" colspan="1">1741 (19.1)</td>
                          <td align="center" rowspan="1" colspan="1">606 (17.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.056</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Myocardial infarction</td>
                          <td align="center" rowspan="1" colspan="1">1039 (11.4)</td>
                          <td align="center" rowspan="1" colspan="1">541 (15.1)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.110</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Coronary artery disease</td>
                          <td align="center" rowspan="1" colspan="1">2104 (23.1)</td>
                          <td align="center" rowspan="1" colspan="1">913 (25.6)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.057</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Peripheral artery disease</td>
                          <td align="center" rowspan="1" colspan="1">355 (3.9)</td>
                          <td align="center" rowspan="1" colspan="1">148 (4.1)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.012</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Cancer</td>
                          <td align="center" rowspan="1" colspan="1">1223 (13.4)</td>
                          <td align="center" rowspan="1" colspan="1">448 (12.5)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.027</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Dementia</td>
                          <td align="center" rowspan="1" colspan="1">76 (0.8)</td>
                          <td align="center" rowspan="1" colspan="1">25 (0.7)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.016</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Gastric ulcer</td>
                          <td align="center" rowspan="1" colspan="1">111 (1.2)</td>
                          <td align="center" rowspan="1" colspan="1">34 (1.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.026</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Gastritis or duodenitis</td>
                          <td align="center" rowspan="1" colspan="1">317 (3.5)</td>
                          <td align="center" rowspan="1" colspan="1">138 (3.9)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.020</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Chronic kidney disease</td>
                          <td align="center" rowspan="1" colspan="1">2663 (29.2)</td>
                          <td align="center" rowspan="1" colspan="1">1218 (34.1)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.104</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> COPD</td>
                          <td align="center" rowspan="1" colspan="1">743 (8.2)</td>
                          <td align="center" rowspan="1" colspan="1">302 (8.5)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.011</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Bleeding (after diagnosis of AF), n (%)</td>
                          <td align="center" rowspan="1" colspan="1">130 (1.4)</td>
                          <td align="center" rowspan="1" colspan="1">52 (1.5)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.002</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Bleeding on OAC, n (%)</td>
                          <td align="center" rowspan="1" colspan="1">112 (86.2)</td>
                          <td align="center" rowspan="1" colspan="1">47 (90.4)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.132</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Location of bleeding (after diagnosis of AF), n (%)<xref ref-type="table-fn" rid="t003fn002">*</xref></td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Intracranial hemorrhage</td>
                          <td align="center" rowspan="1" colspan="1">11 (8.5)</td>
                          <td align="center" rowspan="1" colspan="1">1 (1.9)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.298</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Upper GI bleed</td>
                          <td align="center" rowspan="1" colspan="1">8 (6.2)</td>
                          <td align="center" rowspan="1" colspan="1">4 (7.7)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.061</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Lower GI bleed</td>
                          <td align="center" rowspan="1" colspan="1">20 (15.4)</td>
                          <td align="center" rowspan="1" colspan="1">5 (9.6)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.175</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> GI bleed not further specified</td>
                          <td align="center" rowspan="1" colspan="1">9 (6.9)</td>
                          <td align="center" rowspan="1" colspan="1">2 (3.8)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.137</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Urogenital hemorrhage</td>
                          <td align="center" rowspan="1" colspan="1">20 (15.4)</td>
                          <td align="center" rowspan="1" colspan="1">11 (21.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.150</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Bleeding at other location</td>
                          <td align="center" rowspan="1" colspan="1">56 (43.1)</td>
                          <td align="center" rowspan="1" colspan="1">25 (48.1)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.101</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Bleeding with unknown location</td>
                          <td align="center" rowspan="1" colspan="1">6 (4.6)</td>
                          <td align="center" rowspan="1" colspan="1">4 (7.7)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.128</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> AF cardioversion</td>
                          <td align="center" rowspan="1" colspan="1">1814 (19.9)</td>
                          <td align="center" rowspan="1" colspan="1">521 (14.6)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.142</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Region, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Asia</td>
                          <td align="center" rowspan="1" colspan="1">1222 (13.4)</td>
                          <td align="center" rowspan="1" colspan="1">517 (14.5)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.030</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Europe</td>
                          <td align="center" rowspan="1" colspan="1">4498 (49.4)</td>
                          <td align="center" rowspan="1" colspan="1">2016 (56.4)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.141</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> North America</td>
                          <td align="center" rowspan="1" colspan="1">2808 (30.8)</td>
                          <td align="center" rowspan="1" colspan="1">621 (17.4)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.319</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Latin America</td>
                          <td align="center" rowspan="1" colspan="1">577 (6.3)</td>
                          <td align="center" rowspan="1" colspan="1">418 (11.7)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.188</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Type of site, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> GP/primary care</td>
                          <td align="center" rowspan="1" colspan="1">502 (5.5)</td>
                          <td align="center" rowspan="1" colspan="1">184 (5.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.016</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Specialist office</td>
                          <td align="center" rowspan="1" colspan="1">3053 (33.5)</td>
                          <td align="center" rowspan="1" colspan="1">849 (23.8)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.217</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Community hospital</td>
                          <td align="center" rowspan="1" colspan="1">2880 (31.6)</td>
                          <td align="center" rowspan="1" colspan="1">877 (24.6)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.158</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> University hospital</td>
                          <td align="center" rowspan="1" colspan="1">2454 (27.0)</td>
                          <td align="center" rowspan="1" colspan="1">1424 (39.9)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.276</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Outpatient health care centre</td>
                          <td align="center" rowspan="1" colspan="1">72 (0.8)</td>
                          <td align="center" rowspan="1" colspan="1">150 (4.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.220</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Anticoagulation clinics</td>
                          <td align="center" rowspan="1" colspan="1">37 (0.4)</td>
                          <td align="center" rowspan="1" colspan="1">45 (1.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.094</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Other</td>
                          <td align="center" rowspan="1" colspan="1">107 (1.2)</td>
                          <td align="center" rowspan="1" colspan="1">43 (1.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.003</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t003fn001">
                      <p><sup>a</sup>AF = atrial fibrillation; BMI = body mass index; CHA<sub>2</sub>DS<sub>2</sub>-VASc = congestive heart failure/left ventricular dysfunction, hypertension, age ≥75 years, diabetes, stroke/transient ischemic attack/systemic embolism, vascular disease, age 65–74 years, sex category (female); COPD = chronic obstructive pulmonary disease; EHRA = European Heart Rhythm Association; GI = gastrointestinal; GP = general practitioner; HAS-BLED = hypertension, abnormal renal /liver function, stroke, bleeding history or predisposition, labile International Normalised Ratio, elderly (&gt;65 years), drugs or alcohol concomitantly; NOAC = nonvitamin K antagonist oral anticoagulants; OAC = oral anticoagulant; Q = quartile; TIA = transient ischemic attack; VKA = vitamin K antagonists; y = years.</p>
                    </fn>
                    <fn id="t003fn002">
                      <p>*Proportion calculated out of Bleeding (after diagnosis of AF).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Cardioversion was performed in 19.9% of patients on NOACs vs 14.6% of those on VKAs. Treatment in specialist offices was more prevalent for patients on NOACs (33.5% vs 23.8% in the VKA group), while comorbidities such as heart failure (HF) and MI were less prevalent among patients given NOACs.</p>
                <p>Patient demographics, cardiovascular risk factors, comorbid diseases, AF categorization, stroke and bleeding risks, and concomitant treatments of patients on NOACs QD vs BID are summarized in <xref rid="pone.0249524.t004" ref-type="table">Table 4</xref> There were generally small differences between patients taking NOACs QD vs BID. Previous TIA or stroke were present in 14.9% of the patients on NOACs QD vs 21.3% of the patients on NOACs BID (<xref rid="pone.0249524.t004" ref-type="table">Table 4</xref>).</p>
                <table-wrap id="pone.0249524.t004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0249524.t004</object-id>
                  <label>Table 4</label>
                  <caption>
                    <title>Baseline characteristics of AF multimorbid patients prescribed NOACs QD or NOACs BID.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0249524.t004g" xlink:href="pone.0249524.t004"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="center" rowspan="1" colspan="1">NOAC QD (n = 3071)</th>
                          <th align="center" rowspan="1" colspan="1">NOAC BID (n = 6034)</th>
                          <th align="center" rowspan="1" colspan="1">Standardized Difference</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Age (y), median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">72.0 (65.0–79.0)</td>
                          <td align="center" rowspan="1" colspan="1">73.0 (66.0–79.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.098</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Females, n (%)</td>
                          <td align="center" rowspan="1" colspan="1">1306 (42.5)</td>
                          <td align="center" rowspan="1" colspan="1">2766 (45.8)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.067</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">28.3 (25.0–32.8)</td>
                          <td align="center" rowspan="1" colspan="1">27.9 (24.8–32.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.089</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Current smoker</td>
                          <td align="center" rowspan="1" colspan="1">250 (8.1)</td>
                          <td align="center" rowspan="1" colspan="1">562 (9.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.042</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Alcohol abuse, ≥8 units/ week</td>
                          <td align="center" rowspan="1" colspan="1">242 (7.9)</td>
                          <td align="center" rowspan="1" colspan="1">409 (6.8)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.042</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Type of AF, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Paroxysmal</td>
                          <td align="center" rowspan="1" colspan="1">1767 (57.5)</td>
                          <td align="center" rowspan="1" colspan="1">3420 (56.7)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.017</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Persistent</td>
                          <td align="center" rowspan="1" colspan="1">1045 (34.0)</td>
                          <td align="center" rowspan="1" colspan="1">2007 (33.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.016</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Permanent</td>
                          <td align="center" rowspan="1" colspan="1">259 (8.4)</td>
                          <td align="center" rowspan="1" colspan="1">607 (10.1)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.056</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Categorization of AF, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> EHRA I</td>
                          <td align="center" rowspan="1" colspan="1">1138 (37.1)</td>
                          <td align="center" rowspan="1" colspan="1">2358 (39.1)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.042</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> EHRA II</td>
                          <td align="center" rowspan="1" colspan="1">983 (32.0)</td>
                          <td align="center" rowspan="1" colspan="1">1903 (31.5)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.010</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> EHRA III</td>
                          <td align="center" rowspan="1" colspan="1">775 (25.2)</td>
                          <td align="center" rowspan="1" colspan="1">1356 (22.5)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.065</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> EHRA IV</td>
                          <td align="center" rowspan="1" colspan="1">175 (5.7)</td>
                          <td align="center" rowspan="1" colspan="1">417 (6.9)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.050</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Creatinine clearance (mL/min), (measured), median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">74.4 (55.3–101.8)</td>
                          <td align="center" rowspan="1" colspan="1">70.5 (53.1–94.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.041</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Creatinine clearance, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> &lt;15</td>
                          <td align="center" rowspan="1" colspan="1">18 (0.6)</td>
                          <td align="center" rowspan="1" colspan="1">32 (0.5)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.008</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 15–29</td>
                          <td align="center" rowspan="1" colspan="1">40 (1.3)</td>
                          <td align="center" rowspan="1" colspan="1">108 (1.8)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.040</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 30–49</td>
                          <td align="center" rowspan="1" colspan="1">401 (13.1)</td>
                          <td align="center" rowspan="1" colspan="1">879 (14.6)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.044</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 50–79</td>
                          <td align="center" rowspan="1" colspan="1">1018 (33.1)</td>
                          <td align="center" rowspan="1" colspan="1">2028 (33.6)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.010</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> ≥80</td>
                          <td align="center" rowspan="1" colspan="1">1125 (36.6)</td>
                          <td align="center" rowspan="1" colspan="1">1928 (32.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.099</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Missing</td>
                          <td align="center" rowspan="1" colspan="1">469 (15.3)</td>
                          <td align="center" rowspan="1" colspan="1">1059 (17.6)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.062</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">CHA<sub>2</sub>DS<sub>2</sub>-VASc score, median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">3.0 (2.0–4.0)</td>
                          <td align="center" rowspan="1" colspan="1">4.0 (3.0–5.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.127</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">HAS-BLED score, median (Q1, Q3)</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (1.0–2.0)</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (1.0–2.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.066</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Missing (HAS-BLED), n (%)</td>
                          <td align="center" rowspan="1" colspan="1">302 (9.8)</td>
                          <td align="center" rowspan="1" colspan="1">556 (9.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.021</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Medical history, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Congestive heart failure</td>
                          <td align="center" rowspan="1" colspan="1">772 (25.1)</td>
                          <td align="center" rowspan="1" colspan="1">1460 (24.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.022</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Hypertension</td>
                          <td align="center" rowspan="1" colspan="1">2672 (87.0)</td>
                          <td align="center" rowspan="1" colspan="1">5235 (86.8)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.007</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Diabetes mellitus</td>
                          <td align="center" rowspan="1" colspan="1">1021 (33.2)</td>
                          <td align="center" rowspan="1" colspan="1">1818 (30.1)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.067</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Previous stroke or TIA</td>
                          <td align="center" rowspan="1" colspan="1">457 (14.9)</td>
                          <td align="center" rowspan="1" colspan="1">1284 (21.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.167</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Myocardial infarction</td>
                          <td align="center" rowspan="1" colspan="1">366 (11.9)</td>
                          <td align="center" rowspan="1" colspan="1">673 (11.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.024</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Coronary artery disease</td>
                          <td align="center" rowspan="1" colspan="1">746 (24.3)</td>
                          <td align="center" rowspan="1" colspan="1">1358 (22.5)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.042</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Peripheral artery disease</td>
                          <td align="center" rowspan="1" colspan="1">119 (3.9)</td>
                          <td align="center" rowspan="1" colspan="1">236 (3.9)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.002</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Cancer</td>
                          <td align="center" rowspan="1" colspan="1">407 (13.3)</td>
                          <td align="center" rowspan="1" colspan="1">816 (13.5)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.008</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Dementia</td>
                          <td align="center" rowspan="1" colspan="1">24 (0.8)</td>
                          <td align="center" rowspan="1" colspan="1">52 (0.9)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.009</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Gastric ulcer</td>
                          <td align="center" rowspan="1" colspan="1">40 (1.3)</td>
                          <td align="center" rowspan="1" colspan="1">71 (1.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.011</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Gastritis or duodenitis</td>
                          <td align="center" rowspan="1" colspan="1">116 (3.8)</td>
                          <td align="center" rowspan="1" colspan="1">201 (3.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.024</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Chronic kidney disease</td>
                          <td align="center" rowspan="1" colspan="1">839 (27.3)</td>
                          <td align="center" rowspan="1" colspan="1">1824 (30.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.064</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> COPD</td>
                          <td align="center" rowspan="1" colspan="1">258 (8.4)</td>
                          <td align="center" rowspan="1" colspan="1">485 (8.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.013</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Bleeding (after diagnosis of AF), n (%)</td>
                          <td align="center" rowspan="1" colspan="1">57 (1.9)</td>
                          <td align="center" rowspan="1" colspan="1">73 (1.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.053</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Bleeding on OAC, n (%)</td>
                          <td align="center" rowspan="1" colspan="1">52 (91.2)</td>
                          <td align="center" rowspan="1" colspan="1">60 (82.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.269</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Location of bleeding (after diagnosis of AF), n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Intracranial hemorrhage</td>
                          <td align="center" rowspan="1" colspan="1">2 (3.5)</td>
                          <td align="center" rowspan="1" colspan="1">9 (12.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.331</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Upper GI bleed</td>
                          <td align="center" rowspan="1" colspan="1">4 (7.0)</td>
                          <td align="center" rowspan="1" colspan="1">4 (5.5)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.064</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Lower GI bleed</td>
                          <td align="center" rowspan="1" colspan="1">10 (17.5)</td>
                          <td align="center" rowspan="1" colspan="1">10 (13.7)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.106</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> GI bleed not further specified</td>
                          <td align="center" rowspan="1" colspan="1">5 (8.8)</td>
                          <td align="center" rowspan="1" colspan="1">4 (5.5)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.128</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Urogenital hemorrhage</td>
                          <td align="center" rowspan="1" colspan="1">6 (10.5)</td>
                          <td align="center" rowspan="1" colspan="1">14 (19.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.245</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Bleeding at other location</td>
                          <td align="center" rowspan="1" colspan="1">24 (42.1)</td>
                          <td align="center" rowspan="1" colspan="1">32 (43.8)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.035</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Bleeding with unknown location</td>
                          <td align="center" rowspan="1" colspan="1">6 (10.5)</td>
                          <td align="center" rowspan="1" colspan="1">0 (0.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.438</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> AF cardioversion</td>
                          <td align="center" rowspan="1" colspan="1">710 (23.1)</td>
                          <td align="center" rowspan="1" colspan="1">1104 (18.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.119</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Region, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Asia</td>
                          <td align="center" rowspan="1" colspan="1">356 (11.6)</td>
                          <td align="center" rowspan="1" colspan="1">866 (14.4)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.082</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Europe</td>
                          <td align="center" rowspan="1" colspan="1">1465 (47.7)</td>
                          <td align="center" rowspan="1" colspan="1">3033 (50.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.051</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> North America</td>
                          <td align="center" rowspan="1" colspan="1">1056 (34.4)</td>
                          <td align="center" rowspan="1" colspan="1">1752 (29.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.115</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Latin America</td>
                          <td align="center" rowspan="1" colspan="1">194 (6.3)</td>
                          <td align="center" rowspan="1" colspan="1">383 (6.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Type of site, n (%)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> GP/primary care</td>
                          <td align="center" rowspan="1" colspan="1">184 (6.0)</td>
                          <td align="center" rowspan="1" colspan="1">318 (5.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.031</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Specialist office</td>
                          <td align="center" rowspan="1" colspan="1">1110 (36.1)</td>
                          <td align="center" rowspan="1" colspan="1">1943 (32.2)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.083</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Community hospital</td>
                          <td align="center" rowspan="1" colspan="1">921 (30.0)</td>
                          <td align="center" rowspan="1" colspan="1">1959 (32.5)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.053</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> University hospital</td>
                          <td align="center" rowspan="1" colspan="1">773 (25.2)</td>
                          <td align="center" rowspan="1" colspan="1">1681 (27.9)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.061</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Outpatient health care center</td>
                          <td align="center" rowspan="1" colspan="1">19 (0.6)</td>
                          <td align="center" rowspan="1" colspan="1">53 (0.9)</td>
                          <td align="char" char="." rowspan="1" colspan="1">–0.030</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Anticoagulation clinics</td>
                          <td align="center" rowspan="1" colspan="1">18 (0.6)</td>
                          <td align="center" rowspan="1" colspan="1">19 (0.3)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.041</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Other</td>
                          <td align="center" rowspan="1" colspan="1">46 (1.5)</td>
                          <td align="center" rowspan="1" colspan="1">61 (1.0)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.044</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t004fn001">
                      <p><sup>a</sup>AF = atrial fibrillation; BID = twice daily; BMI = body mass index; CHA<sub>2</sub>DS<sub>2</sub>-VASc = congestive heart failure/left ventricular dysfunction, hypertension, age ≥75 years, diabetes, stroke/transient ischemic attack/systemic embolism, vascular disease, age 65–74 years, sex category (female); COPD = chronic obstructive pulmonary disease; EHRA = European Heart Rhythm Association; GI = gastrointestinal; GP = general practitioner; HAS-BLED = hypertension, abnormal renal /liver function, stroke, bleeding history or predisposition, labile International Normalised Ratio, elderly (&gt;65 years), drugs or alcohol concomitantly; NOAC = nonvitamin K antagonist oral anticoagulants; OAC = oral anticoagulant; Q = quartile; QD = once daily; TIA = transient ischemic attack.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec011">
                <title>Factors associated with OAC non-prescription in multimorbid AF patients globally</title>
                <p>Results from univariate analyses are presented in the <xref ref-type="supplementary-material" rid="pone.0249524.s001">S1 File</xref>. In the multivariable log-binomial regression analysis, factors associated with prescriptions for no OAC use in multimorbid AF patients were: type of AF (paroxysmal/persistent vs permanent), coronary artery disease (CAD), MI, history of bleeding, smoking status (current vs nonsmoker), and region (Asia, North America vs Europe). Factors associated with increased OAC use were: age 65–74 vs ≥75 years, body mass index (BMI) class (≥25 vs 18.5–24 kg/m<sup>2</sup>), creatinine clearance (30–59 vs ≥80 mL/min), hypertension, prior TIA or stroke, and AF ablation (<xref rid="pone.0249524.t005" ref-type="table">Table 5</xref>).</p>
                <table-wrap id="pone.0249524.t005" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0249524.t005</object-id>
                  <label>Table 5</label>
                  <caption>
                    <title>Multivariable log-binomial analysis for factors associated with prescription of OAC therapy (no OAC vs OAC)<xref ref-type="table-fn" rid="t005fn001"><sup>a</sup></xref><sup>,</sup><xref ref-type="table-fn" rid="t005fn002"><sup>b</sup></xref>.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0249524.t005g" xlink:href="pone.0249524.t005"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">Factor</th>
                          <th align="left" rowspan="1" colspan="1">Relative Risk (95% CI) For Prescription of No OAC Globally</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Age</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> &lt;65</td>
                          <td align="center" rowspan="1" colspan="1">1.05 (0.95–1.16)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 65–74</td>
                          <td align="center" rowspan="1" colspan="1">0.90 (0.83–0.99)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> ≥75</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (ref)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">BMI class</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> &lt;18.5</td>
                          <td align="center" rowspan="1" colspan="1">0.98 (0.77–1.24)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 18.5–24</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (ref)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 25–29</td>
                          <td align="center" rowspan="1" colspan="1">0.85 (0.79–0.91)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 30–34</td>
                          <td align="center" rowspan="1" colspan="1">0.77 (0.69–0.87)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> ≥35</td>
                          <td align="center" rowspan="1" colspan="1">0.70 (0.60–0.81)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Gender</td>
                          <td align="left" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Male</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (ref)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Female</td>
                          <td align="center" rowspan="1" colspan="1">1.05 (0.97–1.13)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Current smoker</td>
                          <td align="center" rowspan="1" colspan="1">1.14 (1.03–1.25)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Past smoker</td>
                          <td align="center" rowspan="1" colspan="1">0.91 (0.84–0.99)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Categorization of AF</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">EHRA I</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (ref)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">EHRA II</td>
                          <td align="center" rowspan="1" colspan="1">1.04 (0.96–1.12)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">EHRA III</td>
                          <td align="center" rowspan="1" colspan="1">0.99 (0.91–1.07)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">EHRA IV</td>
                          <td align="center" rowspan="1" colspan="1">1.07 (0.95–1.20)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Type of AF</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Paroxysmal</td>
                          <td align="center" rowspan="1" colspan="1">1.67 (1.42–1.97)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Persistent</td>
                          <td align="center" rowspan="1" colspan="1">1.20 (1.02–1.43)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Permanent</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (ref)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Hypertension</td>
                          <td align="center" rowspan="1" colspan="1">0.89 (0.83–0.97)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Coronary artery disease</td>
                          <td align="center" rowspan="1" colspan="1">1.42 (1.31–1.53)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Myocardial infarction</td>
                          <td align="center" rowspan="1" colspan="1">1.18 (1.08–1.28)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Congestive heart failure</td>
                          <td align="center" rowspan="1" colspan="1">1.01 (0.94–1.08)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Diabetes mellitus</td>
                          <td align="center" rowspan="1" colspan="1">0.95 (0.88–1.02)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Previous TIA or stroke</td>
                          <td align="center" rowspan="1" colspan="1">0.81 (0.68–0.97)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Bleeding after diagnosis of AF</td>
                          <td align="center" rowspan="1" colspan="1">1.60 (1.42–1.79)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Peripheral artery disease</td>
                          <td align="center" rowspan="1" colspan="1">1.13 (0.96–1.34)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Cancer</td>
                          <td align="center" rowspan="1" colspan="1">1.00 (0.90–1.12)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Functional dyspepsia</td>
                          <td align="center" rowspan="1" colspan="1">0.85 (0.56–1.27)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Gastric ulcer</td>
                          <td align="center" rowspan="1" colspan="1">0.91 (0.69–1.21)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Gastritis or duodenitis</td>
                          <td align="center" rowspan="1" colspan="1">0.95 (0.82–1.10)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">COPD</td>
                          <td align="center" rowspan="1" colspan="1">1.03 (0.90–1.19)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Hyperthyroidism</td>
                          <td align="center" rowspan="1" colspan="1">0.96 (0.79–1.17)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Hepatic disease</td>
                          <td align="center" rowspan="1" colspan="1">1.05 (0.87–1.27)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Dementia</td>
                          <td align="center" rowspan="1" colspan="1">1.09 (0.76–1.56)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">AF cardioversion</td>
                          <td align="center" rowspan="1" colspan="1">0.96 (0.89–1.04)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Creatinine clearance (mL/min)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> &lt;30</td>
                          <td align="center" rowspan="1" colspan="1">1.09 (0.94–1.26)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 30–59</td>
                          <td align="center" rowspan="1" colspan="1">0.88 (0.79–0.97)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> 60–79</td>
                          <td align="center" rowspan="1" colspan="1">0.91 (0.83–1.00)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> ≥80</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (ref)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">AF ablation</td>
                          <td align="center" rowspan="1" colspan="1">0.30 (0.20–0.45)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Region</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Asia</td>
                          <td align="center" rowspan="1" colspan="1">3.17 (2.88–3.49)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Europe</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (ref)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> North America</td>
                          <td align="center" rowspan="1" colspan="1">1.24 (1.11–1.39)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Latin America</td>
                          <td align="center" rowspan="1" colspan="1">1.14 (0.96–1.37)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Medical treatment reimbursed by</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Self-pay/no coverage</td>
                          <td align="center" rowspan="1" colspan="1">0.82 (0.69–0.96)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Not self-pay</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (ref)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Type of site</td>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Specialist office</td>
                          <td align="center" rowspan="1" colspan="1">1.26 (1.14–1.39)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> Community hospital</td>
                          <td align="center" rowspan="1" colspan="1">1.0 (ref)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> University hospital</td>
                          <td align="center" rowspan="1" colspan="1">1.28 (1.17–1.40)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t005fn001">
                      <p><sup>a</sup>A few other variables (alcohol abuse, psychosocial factors, biological heart valve implant, valve repair, and peptic ulcer) are included in the multivariable log-binomial regression analysis model and are presented in the <xref ref-type="supplementary-material" rid="pone.0249524.s001">S1 File</xref>.</p>
                    </fn>
                    <fn id="t005fn002">
                      <p><sup>b</sup>AF = atrial fibrillation; BMI = body mass index; CI = confidence interval; COPD = chronic obstructive pulmonary disease; EHRA = European Heart Rhythm Association; OAC = oral anticoagulant; ref = reference; TIA = transient ischemic attack.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec012">
                <title>Factors associated with OACs non-prescription in multimorbid AF patients in Asia, Europe, and North America</title>
                <p>Factors associated with prescriptions for no OAC use in multimorbid AF patients in Asia, Europe, and North America are presented in <bold>S1 Table in</bold>
<xref ref-type="supplementary-material" rid="pone.0249524.s002">S2 File</xref>. Factors associated with increased OAC use are included in <bold>S1 Table in</bold>
<xref ref-type="supplementary-material" rid="pone.0249524.s002">S2 File</xref>.</p>
              </sec>
              <sec id="sec013">
                <title>Factors associated with type of OAC use in multimorbid AF patients globally</title>
                <p>Factors associated with prescriptions for VKA use globally in multimorbid AF patients were: age &lt;75 vs ≥75 years, MI, congestive HF, diabetes mellitus, creatinine clearance (&lt;60 vs ≥80 mL/min), <bold>S2 Table in</bold>
<xref ref-type="supplementary-material" rid="pone.0249524.s002">S2 File</xref>.</p>
                <p>Factors associated with decreased VKA use globally were: type of AF (paroxysmal/persistent vs permanent), previous TIA or stroke, medical treatment reimbursement (self-pay/no coverage vs not self-pay), <bold>S2 Table in</bold>
<xref ref-type="supplementary-material" rid="pone.0249524.s002">S2 File</xref>.</p>
              </sec>
              <sec id="sec014">
                <title>Factors associated with OAC use in multimorbid AF patients in Asia, Europe, North America, and Latin America</title>
                <p>Factors associated with prescriptions for VKA use in multimorbid AF patients in Asia, Europe, North America, and Latin America are presented in <bold>S3 Table in</bold>
<xref ref-type="supplementary-material" rid="pone.0249524.s002">S2 File</xref>. Factors associated with decreased prescriptions for VKA use in multimorbid AF patients in Asia, Europe, North America, and Latin America are presented in <bold>S3 Table in</bold>
<xref ref-type="supplementary-material" rid="pone.0249524.s002">S2 File</xref>.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec015">
              <title>Discussion</title>
              <p>There are still knowledge gaps in how OACs are used in clinical practice in patients with AF and multiple comorbidities and which factors influence OAC prescription in such patients. Our study shows that, despite a median CHA<sub>2</sub>DS<sub>2</sub>-VASc score &gt;3, approximately 16% of patients with multimorbidity and AF are not anticoagulated. The baseline characteristics in these complex patients differ in relation to antithrombotic therapy selection, suggesting that comorbidities may influence antithrombotic therapy prescription patterns for patients with AF. For example, prescription of OACs globally in patients with AF and multimorbidity was associated with age, BMI, cardiovascular risk factors (smoking status), AF pattern, concomitant diseases (ie, hypertension, CAD, MI, previous TIA or stroke), history of bleeding, renal function, rhythm control strategy (AF ablation and AF cardioversion), and region (Asia and North America). Prescriptions patterns were also subject to regional differences in clinical practice.</p>
              <sec id="sec016">
                <title>Patient characteristics according to antithrombotic therapy use</title>
                <p>The results suggest that patients with AF and multimorbidity prescribed NOACs are more likely to have paroxysmal AF, and have fewer comorbidities than those prescribed VKAs, consistent with other reports [<xref rid="pone.0249524.ref013" ref-type="bibr">13</xref>–<xref rid="pone.0249524.ref015" ref-type="bibr">15</xref>]. Declining renal function may influence the choice of VKA in those with chronic kidney disease. Healthcare system-related factors (such as center type) also influence treatment strategies. Patients with AF and multimorbidity treated in specialist offices and community hospitals are more often prescribed NOACs than VKAs.</p>
                <p>The patients in this cohort prescribed antiplatelet agents had a higher risk of bleeding according to HAS-BLED score than those who were prescribed OACs. They also more often had paroxysmal AF compared to those prescribed OACs. Patients with AF and CAD were more often prescribed antiplatelets than OACs despite the fact that antiplatelet therapy does not prevent stroke or reduce mortality, elevates the risk of bleeding, and is not recommended for prevention of AF-related thromboembolism [<xref rid="pone.0249524.ref016" ref-type="bibr">16</xref>]. Unfortunately, antiplatelet monotherapy is still a frequent choice of prescribing physicians based on several European reports [<xref rid="pone.0249524.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0249524.ref018" ref-type="bibr">18</xref>].</p>
              </sec>
              <sec id="sec017">
                <title>Factors associated with OAC prescription in multimorbid AF patients globally</title>
                <p>The majority of multimorbid AF patients had a high risk of stroke (CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥2) and oral anticoagulation therapy is recommended for these patients [<xref rid="pone.0249524.ref019" ref-type="bibr">19</xref>]. Hypertension and HF were the most prevalent risk factors for thromboembolic complications [<xref rid="pone.0249524.ref020" ref-type="bibr">20</xref>] and these factors and previous stroke or TIA are associated with a greater frequency of OAC prescription. Prescription of OACs was inversely associated with comorbidities that are strongly associated with elevated thromboembolic risk (eg, MI, CAD), just as conditions associated with an increased risk of bleeding (eg, previous hemorrhagic events) were associated with less frequent prescription of OACs. This is also consistent with prior reports [<xref rid="pone.0249524.ref013" ref-type="bibr">13</xref>] although current clinical practice guidelines recommend that patients with AF at a high risk of bleeding should generally continue anticoagulation with frequent visits and close monitoring [<xref rid="pone.0249524.ref021" ref-type="bibr">21</xref>]. A history of AF ablation in multimorbid AF patients was associated with more frequent OAC prescription as per guidelines [<xref rid="pone.0249524.ref021" ref-type="bibr">21</xref>] and consistent with other studies [<xref rid="pone.0249524.ref022" ref-type="bibr">22</xref>].</p>
                <p>Younger age (≤75 years) was associated with greater OAC prescription and more frequent selection of VKAs compared to practice patterns for older patients. Several studies have suggested that increasing age is a barrier to implementing OAC use [<xref rid="pone.0249524.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0249524.ref024" ref-type="bibr">24</xref>]. Importantly, stroke risk increases with age, and the absolute benefit of OACs is clearly increased for older patients with AF [<xref rid="pone.0249524.ref025" ref-type="bibr">25</xref>]. In one report, when adjusted for comorbidity, age was not an important determinant of anticoagulation [<xref rid="pone.0249524.ref026" ref-type="bibr">26</xref>].</p>
                <p>Multimorbid AF patients with paroxysmal or persistent AF were less often prescribed OACs in particular VKAs than those with permanent AF. NOACs should be preferred in patients with multimorbidity and polypharmacy given their lower number of drug–drug interactions compared with VKAs [<xref rid="pone.0249524.ref027" ref-type="bibr">27</xref>]. Ischemic stroke may occur as frequently in paroxysmal AF as in permanent AF, especially with multiple risk factors [<xref rid="pone.0249524.ref028" ref-type="bibr">28</xref>]. Moreover, the use of OACs should be based on stroke risk assessment according to the CHA<sub>2</sub>DS<sub>2</sub>-VASc risk score [<xref rid="pone.0249524.ref021" ref-type="bibr">21</xref>]. The pattern of AF seems to be related to patient profiles characterized by age, concomitant diseases, symptoms, and risk factors for stroke and bleeding [<xref rid="pone.0249524.ref013" ref-type="bibr">13</xref>]. Patients with higher European Heart Rhythm Association symptom scores were more often prescribed VKAs than those who were asymptomatic.</p>
                <p>Multimorbid AF patients with a history of cardioversion were less often prescribed VKAs than those without prior cardioversion. NOACs were preferred in multimorbid AF patients after cardioversion. A similar pattern was found in another study where rhythm control strategy was associated with selection of NOAC [<xref rid="pone.0249524.ref014" ref-type="bibr">14</xref>].</p>
              </sec>
              <sec id="sec018">
                <title>OAC prescription in multimorbid AF patients regionally</title>
                <p>In this study, multimorbidity influenced ATT use within particular regions. In Europe, younger patients (age &lt;65 years) were less likely to be prescribed OACs than older patients (age ≥75 years). Multimorbid AF patients with congestive HF were more likely to be anticoagulated due to an increased risk of thromboembolism. In Europe, bleeding risk of a patient as perceived by physicians may be the reason for decreased use of anticoagulation. Patients with gastritis or duodenitis or hepatic disease are less likely to be prescribed OACs, probably because of the elevated risk of bleeding. This association has been previously noted [<xref rid="pone.0249524.ref026" ref-type="bibr">26</xref>]. In Asia, younger patients (age &lt;75 years) were more likely to be prescribed OACs than older patients (age ≥75 years). Interestingly, patients with gastritis or duodenitis or a history of cancer were more likely to receive OAC than those without those diseases. In North America, younger multimorbid AF patients (age &lt;65 years) were less likely to be prescribed OACs than older patients (age ≥75 years). Multimorbid AF patients with diabetes were more likely to receive OACs, due to their association with higher thromboembolic risk, as well as higher all-cause, cardiovascular, and noncardiovascular mortality [<xref rid="pone.0249524.ref029" ref-type="bibr">29</xref>]. AF patients with multimorbidity and cancer in North America were less likely to receive OAC.</p>
                <p>Asia and North America were associated with decreased OAC prescription. In Asia, OACs are less commonly prescribed in nonvalvular AF patients than in Europe, possibly because of suspicion of the risk of bleeding during treatment [<xref rid="pone.0249524.ref030" ref-type="bibr">30</xref>]. Also, NOACs are not reimbursed in some Asian countries.</p>
              </sec>
              <sec id="sec019">
                <title>Strengths</title>
                <p>It is one the largest prospective global cohort of consecutive AF patients receiving different antithrombotic treatments. Initiation of Phase III was region-specific, once relevant baseline characteristics of patients initiating dabigatran and VKA therapy in Phase II overlapped based on propensity score comparisons. After the baseline visit, all patients in this Phase III were managed according to local clinical practice and were followed for 3 years, regardless of prescribed antithrombotic therapy. This study had regular follow-up with physicians, alongside on-site monitoring, multiple standards for data quality assurance and review.</p>
              </sec>
              <sec id="sec020">
                <title>Limitations</title>
                <p>Although the GLORIA-AF study was designed to capture all outcome events, this analysis did not consider follow-up data. The following limitations exist in our study: we have no data on patient and prescriber treatment preferences; similarly, reasons for OAC nonprescription were not reported. Furthermore, this study reflects single, initial-treatment decisions during a period when prescribing patterns may have been changing, and the analysis was based on prescription pattern shortly after entry into the registry (baseline). Neither have we accounted for quality of anticoagulation or changes in clinical practice patterns over time.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec021">
              <title>Conclusion</title>
              <p>AF patients with multimorbidity who were prescribed NOACs were relatively healthier, more likely to have paroxysmal AF, and had fewer prevalent comorbidities than AF multimorbid patients on VKAs. Multimorbidity may determine the antithrombotic therapy prescription pattern within AF patients. Several factors are related to increased OAC prescription in multimorbid AF patients, including younger age, hypertension, prior TIA or stroke, and AF ablation. Pattern of AF (paroxysmal and persistent AF), CAD, MI, history of bleeding, and region (Asia, North America) were inversely associated with OAC prescription.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sec022">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="pone.0249524.s001">
                <label>S1 File</label>
                <caption>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0249524.s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0249524.s002">
                <label>S2 File</label>
                <caption>
                  <p>(ODT)</p>
                </caption>
                <media xlink:href="pone.0249524.s002.odt">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>The authors thank the patients who participated in this trial, their families, the investigators, study co-ordinators, and study teams.</p>
              <p>GLORIA_AF Phase III Participating Investigator listing.</p>
              <p>Dzifa Wosornu Abban</p>
              <p>Nasser Abdul</p>
              <p>Atilio Marcelo Abud</p>
              <p>Fran Adams</p>
              <p>Srinivas Addala</p>
              <p>Pedro Adragão</p>
              <p>Walter Ageno</p>
              <p>Rajesh Aggarwal</p>
              <p>Sergio Agosti</p>
              <p>Piergiuseppe Agostoni</p>
              <p>Francisco Aguilar</p>
              <p>Julio Aguilar Linares</p>
              <p>Luis Aguinaga</p>
              <p>Jameel Ahmed</p>
              <p>Allessandro Aiello</p>
              <p>Paul Ainsworth</p>
              <p>Jorge Roberto Aiub</p>
              <p>Raed Al-Dallow</p>
              <p>Lisa Alderson</p>
              <p>Jorge Antonio Aldrete Velasco</p>
              <p>Dimitrios Alexopoulos</p>
              <p>Fernando Alfonso Manterola</p>
              <p>Pareed Aliyar</p>
              <p>David Alonso</p>
              <p>Fernando Augusto Alves da Costa</p>
              <p>José Amado</p>
              <p>Walid Amara</p>
              <p>Mathieu Amelot</p>
              <p>Nima Amjadi</p>
              <p>Fabrizio Ammirati</p>
              <p>Marianna Andrade</p>
              <p>Nabil Andrawis</p>
              <p>Giorgio Annoni</p>
              <p>Gerardo Ansalone</p>
              <p>M.Kevin Ariani</p>
              <p>Juan Carlos Arias</p>
              <p>Sébastien Armero</p>
              <p>Chander Arora</p>
              <p>Muhammad Shakil Aslam</p>
              <p>M. Asselman</p>
              <p>Philippe Audouin</p>
              <p>Charles Augenbraun</p>
              <p>S. Aydin</p>
              <p>Ivaneta Ayryanova</p>
              <p>Emad Aziz</p>
              <p>Luciano Marcelo Backes</p>
              <p>E. Badings</p>
              <p>Ermentina Bagni</p>
              <p>Seth H. Baker</p>
              <p>Richard Bala</p>
              <p>Antonio Baldi</p>
              <p>Shigenobu Bando</p>
              <p>Subhash Banerjee</p>
              <p>Alan Bank</p>
              <p>Gonzalo Barón Esquivias</p>
              <p>Craig Barr</p>
              <p>Maria Bartlett</p>
              <p>Vanja Basic Kes</p>
              <p>Giovanni Baula</p>
              <p>Steffen Behrens</p>
              <p>Alan Bell</p>
              <p>Raffaella Benedetti</p>
              <p>Juan Benezet Mazuecos</p>
              <p>Bouziane Benhalima</p>
              <p>Jutta Bergler-Klein</p>
              <p>Jean-Baptiste Berneau</p>
              <p>Richard A. Bernstein</p>
              <p>Percy Berrospi</p>
              <p>Sergio Berti</p>
              <p>Andrea Berz</p>
              <p>Elizabeth Best</p>
              <p>Paulo Bettencourt</p>
              <p>Robert Betzu</p>
              <p>Ravi Bhagwat</p>
              <p>Luna Bhatta</p>
              <p>Francesco Biscione</p>
              <p>Giovanni BISIGNANI</p>
              <p>Toby Black</p>
              <p>Michael J. Bloch</p>
              <p>Stephen Bloom</p>
              <p>Edwin Blumberg</p>
              <p>Mario Bo</p>
              <p>Ellen Bøhmer</p>
              <p>Andreas Bollmann</p>
              <p>Maria Grazia Bongiorni</p>
              <p>Giuseppe Boriani</p>
              <p>D.J. Boswijk</p>
              <p>Jochen Bott</p>
              <p>Edo Bottacchi</p>
              <p>Marica Bracic Kalan</p>
              <p>Drew Bradman</p>
              <p>Donald Brautigam</p>
              <p>Nicolas Breton</p>
              <p>P.J.A.M. Brouwers</p>
              <p>Kevin Browne</p>
              <p>Jordi Bruguera Cortada</p>
              <p>A. Bruni</p>
              <p>Claude Brunschwig</p>
              <p>Hervé Buathier</p>
              <p>Aurélie Buhl</p>
              <p>John Bullinga</p>
              <p>Jose Walter Cabrera</p>
              <p>Alberto Caccavo</p>
              <p>Shanglang Cai</p>
              <p>Sarah Caine</p>
              <p>Leonardo Calò</p>
              <p>Valeria Calvi</p>
              <p>Mauricio Camarillo Sánchez</p>
              <p>Rui Candeias</p>
              <p>Vincenzo Capuano</p>
              <p>Alessandro Capucci</p>
              <p>Ronald Caputo</p>
              <p>Tatiana Cárdenas Rizo</p>
              <p>Francisco Cardona</p>
              <p>Francisco Carlos da Costa Darrieux</p>
              <p>Yan Carlos Duarte Vera</p>
              <p>Antonio Carolei</p>
              <p>Susana Carreño</p>
              <p>Paula Carvalho</p>
              <p>Susanna Cary</p>
              <p>Gavino Casu</p>
              <p>Claudio Cavallini</p>
              <p>Guillaume Cayla</p>
              <p>Aldo Celentano</p>
              <p>Tae-Joon Cha</p>
              <p>Kwang Soo Cha</p>
              <p>Jei Keon Chae</p>
              <p>Kathrine Chalamidas</p>
              <p>Krishnan Challappa</p>
              <p>Sunil Prakash Chand</p>
              <p>Harinath Chandrashekar</p>
              <p>Ludovic Chartier</p>
              <p>Kausik Chatterjee</p>
              <p>Carlos Antero Chavez Ayala</p>
              <p>Aamir Cheema</p>
              <p>Amjad Cheema</p>
              <p>Lin Chen</p>
              <p>Shih-Ann Chen</p>
              <p>Jyh Hong Chen</p>
              <p>Fu-Tien Chiang</p>
              <p>Francesco Chiarella</p>
              <p>Lin Chih-Chan</p>
              <p>Yong Keun Cho</p>
              <p>Jong-Il Choi</p>
              <p>Dong Ju Choi</p>
              <p>Guy Chouinard</p>
              <p>Danny Hoi-Fan Chow</p>
              <p>Dimitrios Chrysos</p>
              <p>Galina Chumakova</p>
              <p>Eduardo Julián José Roberto Chuquiure Valenzuela</p>
              <p>Nicoleta Cindea Nica</p>
              <p>David J. Cislowski</p>
              <p>Anthony Clay</p>
              <p>Piers Clifford</p>
              <p>Andrew Cohen</p>
              <p>Michael Cohen</p>
              <p>Serge Cohen</p>
              <p>Furio Colivicchi</p>
              <p>Ronan Collins</p>
              <p>Paolo Colonna</p>
              <p>Steve Compton</p>
              <p>Derek Connolly</p>
              <p>Alberto Conti</p>
              <p>Gabriel Contreras Buenostro</p>
              <p>Gregg Coodley</p>
              <p>Martin Cooper</p>
              <p>Julian Coronel</p>
              <p>Giovanni Corso</p>
              <p>Juan Cosín Sales</p>
              <p>Yves Cottin</p>
              <p>John Covalesky</p>
              <p>Aurel Cracan</p>
              <p>Filippo Crea</p>
              <p>Peter Crean</p>
              <p>James Crenshaw</p>
              <p>Tina Cullen</p>
              <p>Harald Darius</p>
              <p>Patrick Dary</p>
              <p>Olivier Dascotte</p>
              <p>Ira Dauber</p>
              <p>Vicente Davalos</p>
              <p>Ruth Davies</p>
              <p>Gershan Davis</p>
              <p>Jean-Marc Davy</p>
              <p>Mark Dayer</p>
              <p>Marzia De Biasio</p>
              <p>Silvana De Bonis</p>
              <p>Raffaele De Caterina</p>
              <p>Teresiano De Franceschi</p>
              <p>J.R. de Groot</p>
              <p>José De Horta</p>
              <p>Axel De La Briolle</p>
              <p>Gilberto de la Pena Topete</p>
              <p>Angelo Amato Vicenzo de Paola</p>
              <p>Weimar de Souza</p>
              <p>A. de Veer</p>
              <p>Luc De Wolf</p>
              <p>Eric Decoulx</p>
              <p>Sasalu Deepak</p>
              <p>Pascal Defaye</p>
              <p>Freddy Del-Carpio Munoz</p>
              <p>Diana Delic Brkljacic</p>
              <p>N. Joseph Deumite</p>
              <p>Silvia Di Legge</p>
              <p>Igor Diemberger</p>
              <p>Denise Dietz</p>
              <p>Pedro Dionísio</p>
              <p>Qiang Dong</p>
              <p>Fabio Rossi dos Santos</p>
              <p>Elena Dotcheva</p>
              <p>Rami Doukky</p>
              <p>Anthony D’Souza</p>
              <p>Simon Dubrey</p>
              <p>Xavier Ducrocq</p>
              <p>Dmitry Dupljakov</p>
              <p>Mauricio Duque</p>
              <p>Dipankar Dutta</p>
              <p>Nathalie Duvilla</p>
              <p>A. Duygun</p>
              <p>Rainer Dziewas</p>
              <p>Charles B. Eaton</p>
              <p>William Eaves</p>
              <p>L.A Ebels-Tuinbeek</p>
              <p>Clifford Ehrlich</p>
              <p>Sabine Eichinger-Hasenauer</p>
              <p>Steven J. Eisenberg</p>
              <p>Adnan El Jabali</p>
              <p>Mahfouz El Shahawy</p>
              <p>Mauro Esteves Hernandes</p>
              <p>Ana Etxeberria Izal</p>
              <p>Rudolph Evonich III</p>
              <p>Oksana Evseeva</p>
              <p>Andrey Ezhov</p>
              <p>Raed Fahmy</p>
              <p>Quan Fang</p>
              <p>Ramin Farsad</p>
              <p>Laurent Fauchier</p>
              <p>Stefano Favale</p>
              <p>Maxime Fayard</p>
              <p>Jose Luis Fedele</p>
              <p>Francesco Fedele</p>
              <p>Olga Fedorishina</p>
              <p>Steven R. Fera</p>
              <p>Luis Gustavo Gomes Ferreira</p>
              <p>Jorge Ferreira</p>
              <p>Claudio Ferri</p>
              <p>Anna Ferrier</p>
              <p>Hugo Ferro</p>
              <p>Alexandra Finsen</p>
              <p>Brian First</p>
              <p>Stuart Fischer</p>
              <p>Catarina Fonseca</p>
              <p>Luísa Fonseca Almeida</p>
              <p>Steven Forman</p>
              <p>Brad Frandsen</p>
              <p>William French</p>
              <p>Keith Friedman</p>
              <p>Athena Friese</p>
              <p>Ana Gabriela Fruntelata</p>
              <p>Shigeru Fujii</p>
              <p>Stefano Fumagalli</p>
              <p>Marta Fundamenski</p>
              <p>Yutaka Furukawa</p>
              <p>Matthias Gabelmann</p>
              <p>Nashwa Gabra</p>
              <p>Niels Gadsbøll</p>
              <p>Michel Galinier</p>
              <p>Anders Gammelgaard</p>
              <p>Priya Ganeshkumar</p>
              <p>Christopher Gans</p>
              <p>Antonio Garcia Quintana</p>
              <p>Olivier Gartenlaub</p>
              <p>Achille Gaspardone</p>
              <p>Conrad Genz</p>
              <p>Frédéric Georger</p>
              <p>Jean-Louis Georges</p>
              <p>Steven Georgeson</p>
              <p>Evaldas Giedrimas</p>
              <p>Mariusz Gierba</p>
              <p>Ignacio Gil Ortega</p>
              <p>Eve Gillespie</p>
              <p>Alberto Giniger</p>
              <p>Michael C. Giudici</p>
              <p>Alexandros Gkotsis</p>
              <p>Taya V. Glotzer</p>
              <p>Joachim Gmehling</p>
              <p>Jacek Gniot</p>
              <p>Peter Goethals</p>
              <p>Seth Goldbarg</p>
              <p>Ronald Goldberg</p>
              <p>Britta Goldmann</p>
              <p>Sergey Golitsyn</p>
              <p>Silvia Gómez</p>
              <p>Juan Gomez Mesa</p>
              <p>Vicente Bertomeu Gonzalez</p>
              <p>Jesus Antonio Gonzalez Hermosillo</p>
              <p>Víctor Manuel González López</p>
              <p>Hervé Gorka</p>
              <p>Charles Gornick</p>
              <p>Diana Gorog</p>
              <p>Venkat Gottipaty</p>
              <p>Pascal Goube</p>
              <p>Ioannis Goudevenos</p>
              <p>Brett Graham</p>
              <p>G. Stephen Greer</p>
              <p>Uwe Gremmler</p>
              <p>Paul G. Grena</p>
              <p>Martin Grond</p>
              <p>Edoardo Gronda</p>
              <p>Gerian Grönefeld</p>
              <p>Xiang Gu</p>
              <p>Ivett Guadalupe Torres Torres</p>
              <p>Gabriele Guardigli</p>
              <p>Carolina Guevara</p>
              <p>Alexandre Guignier</p>
              <p>Michele Gulizia</p>
              <p>Michael Gumbley</p>
              <p>Albrecht Günther</p>
              <p>Andrew Ha</p>
              <p>Georgios Hahalis</p>
              <p>Joseph Hakas</p>
              <p>Christian Hall</p>
              <p>Bing Han</p>
              <p>Seongwook Han</p>
              <p>Joe Hargrove</p>
              <p>David Hargroves</p>
              <p>Kenneth B. Harris</p>
              <p>Tetsuya Haruna</p>
              <p>Emil Hayek</p>
              <p>Jeff Healey</p>
              <p>Steven Hearne</p>
              <p>Michael Heffernan</p>
              <p>Geir Heggelund</p>
              <p>J.A. Heijmeriks</p>
              <p>Maarten Hemels</p>
              <p>I. Hendriks</p>
              <p>Sam Henein</p>
              <p>Sung-Ho Her</p>
              <p>Paul Hermany</p>
              <p>Jorge Eduardo Hernández Del Río</p>
              <p>Yorihiko Higashino</p>
              <p>Michael Hill</p>
              <p>Tetsuo Hisadome</p>
              <p>Eiji Hishida</p>
              <p>Etienne Hoffer</p>
              <p>Matthew Hoghton</p>
              <p>Kui Hong</p>
              <p>Suk keun Hong</p>
              <p>Stevie Horbach</p>
              <p>Masataka Horiuchi</p>
              <p>Yinglong Hou</p>
              <p>Jeff Hsing</p>
              <p>Chi-Hung Huang</p>
              <p>David Huckins</p>
              <p>kathy Hughes</p>
              <p>A. Huizinga</p>
              <p>E.L. Hulsman</p>
              <p>Kuo-Chun Hung</p>
              <p>Gyo-Seung Hwang</p>
              <p>Margaret Ikpoh</p>
              <p>Davide Imberti</p>
              <p>Hüseyin Ince</p>
              <p>Ciro Indolfi</p>
              <p>Shujiro Inoue</p>
              <p>Didier Irles</p>
              <p>Harukazu Iseki</p>
              <p>C. Noah Israel</p>
              <p>Bruce Iteld</p>
              <p>Venkat Iyer</p>
              <p>Ewart Jackson-Voyzey</p>
              <p>Naseem Jaffrani</p>
              <p>Frank Jäger</p>
              <p>Martin James</p>
              <p>Sung-Won Jang</p>
              <p>Nicolas Jaramillo</p>
              <p>Nabil Jarmukli</p>
              <p>Robert J. Jeanfreau</p>
              <p>Ronald D. Jenkins</p>
              <p>Carlos Jerjes Sánchez</p>
              <p>Javier Jimenez</p>
              <p>Robert Jobe</p>
              <p>Tomas Joen-Jakobsen</p>
              <p>Nicholas Jones</p>
              <p>Jose Carlos Moura Jorge</p>
              <p>Bernard Jouve</p>
              <p>Byung Chun Jung</p>
              <p>Kyung Tae Jung</p>
              <p>Werner Jung</p>
              <p>Mikhail Kachkovskiy</p>
              <p>Krystallenia Kafkala</p>
              <p>Larisa Kalinina</p>
              <p>Bernd Kallmünzer</p>
              <p>Farzan Kamali</p>
              <p>Takehiro Kamo</p>
              <p>Priit Kampus</p>
              <p>Hisham Kashou</p>
              <p>Andreas Kastrup</p>
              <p>Apostolos Katsivas</p>
              <p>Elizabeth Kaufman</p>
              <p>Kazuya Kawai</p>
              <p>Kenji Kawajiri</p>
              <p>John F. Kazmierski</p>
              <p>P Keeling</p>
              <p>José Francisco Kerr Saraiva</p>
              <p>Galina Ketova</p>
              <p>AJIT Singh Khaira</p>
              <p>Aleksey Khripun</p>
              <p>Doo-Il Kim</p>
              <p>Young Hoon Kim</p>
              <p>Nam Ho Kim</p>
              <p>Dae Kyeong Kim</p>
              <p>Jeong Su Kim</p>
              <p>June Soo Kim</p>
              <p>Ki Seok Kim</p>
              <p>Jin bae Kim</p>
              <p>Elena Kinova</p>
              <p>Alexander Klein</p>
              <p>James J. Kmetzo</p>
              <p>G. Larsen Kneller</p>
              <p>Aleksandar Knezevic</p>
              <p>Su Mei Angela Koh</p>
              <p>Shunichi Koide</p>
              <p>Athanasios Kollias</p>
              <p>J.A. Kooistra</p>
              <p>Jay Koons</p>
              <p>Martin Koschutnik</p>
              <p>William J. Kostis</p>
              <p>Dragan Kovacic</p>
              <p>Jacek Kowalczyk</p>
              <p>Natalya Koziolova</p>
              <p>Peter Kraft</p>
              <p>Johannes A. Kragten</p>
              <p>Mori Krantz</p>
              <p>Lars Krause</p>
              <p>B.J. Krenning</p>
              <p>F. Krikke</p>
              <p>Z. Kromhout</p>
              <p>Waldemar Krysiak</p>
              <p>Priya Kumar</p>
              <p>Thomas Kümler</p>
              <p>Malte Kuniss</p>
              <p>Jen-Yuan Kuo</p>
              <p>Achim Küppers</p>
              <p>Karla Kurrelmeyer</p>
              <p>Choong Hwan Kwak</p>
              <p>Bénédicte Laboulle</p>
              <p>Arthur Labovitz</p>
              <p>Wen Ter Lai</p>
              <p>Andy Lam</p>
              <p>Yat Yin Lam</p>
              <p>Fernando Lanas Zanetti</p>
              <p>Charles Landau</p>
              <p>Giancarlo Landini</p>
              <p>Estêvão Lanna Figueiredo</p>
              <p>Torben Larsen</p>
              <p>Karine Lavandier</p>
              <p>Jessica LeBlanc</p>
              <p>Moon Hyoung Lee</p>
              <p>Chang-Hoon Lee</p>
              <p>John Lehman</p>
              <p>Ana Leitão</p>
              <p>Nicolas Lellouche</p>
              <p>Malgorzata Lelonek</p>
              <p>Radoslaw Lenarczyk</p>
              <p>T. Lenderink</p>
              <p>Salvador León González</p>
              <p>Peter Leong-Sit</p>
              <p>Matthias Leschke</p>
              <p>Nicolas Ley</p>
              <p>Zhanquan Li</p>
              <p>Xiaodong Li</p>
              <p>Weihua Li</p>
              <p>Xiaoming Li</p>
              <p>Christhoh Lichy</p>
              <p>Ira Lieber</p>
              <p>Ramon Horacio Limon Rodriguez</p>
              <p>Hailong Lin</p>
              <p>Gregory Y. H. Lip</p>
              <p>Feng Liu</p>
              <p>Hengliang Liu</p>
              <p>Guillermo Llamas Esperon</p>
              <p>Nassip Llerena Navarro</p>
              <p>Eric Lo</p>
              <p>Sergiy Lokshyn</p>
              <p>Amador López</p>
              <p>José Luís López-Sendón</p>
              <p>Adalberto Menezes Lorga Filho</p>
              <p>Richard S. Lorraine</p>
              <p>Carlos Alberto Luengas</p>
              <p>Robert Luke</p>
              <p>Ming Luo</p>
              <p>Steven Lupovitch</p>
              <p>Philippe Lyrer</p>
              <p>Changsheng Ma</p>
              <p>Genshan Ma</p>
              <p>Irene Madariaga</p>
              <p>Koji Maeno</p>
              <p>Dominique Magnin</p>
              <p>Gustavo Maid</p>
              <p>Sumeet K. Mainigi</p>
              <p>Konstantinos Makaritsis</p>
              <p>Rohit Malhotra</p>
              <p>Rickey Manning</p>
              <p>Athanasios Manolis</p>
              <p>Helard Andres Manrique Hurtado</p>
              <p>Ioannis Mantas</p>
              <p>Fernando Manzur Jattin</p>
              <p>Vicky Maqueda</p>
              <p>Niccolo Marchionni</p>
              <p>Francisco Marin Ortuno</p>
              <p>Antonio Martín Santana</p>
              <p>Jorge Martinez</p>
              <p>Petra Maskova</p>
              <p>Norberto Matadamas Hernandez</p>
              <p>Katsuhiro Matsuda</p>
              <p>Tillmann Maurer</p>
              <p>Ciro Mauro</p>
              <p>Erik May</p>
              <p>Nolan Mayer</p>
              <p>John McClure</p>
              <p>Terry McCormack</p>
              <p>William McGarity</p>
              <p>Hugh McIntyre</p>
              <p>Brent McLaurin</p>
              <p>Feliz Alvaro Medina Palomino</p>
              <p>Francesco Melandri</p>
              <p>Hiroshi Meno</p>
              <p>Dhananjai Menzies</p>
              <p>Marco Mercader</p>
              <p>Christian Meyer</p>
              <p>Beat j. Meyer</p>
              <p>Jacek Miarka</p>
              <p>Frank Mibach</p>
              <p>Dominik Michalski</p>
              <p>Patrik Michel</p>
              <p>Rami Mihail Chreih</p>
              <p>Ghiath Mikdadi</p>
              <p>Milan Mikus</p>
              <p>Davor Milicic</p>
              <p>Constantin Militaru</p>
              <p>Sedi Minaie</p>
              <p>Bogdan Minescu</p>
              <p>Iveta Mintale</p>
              <p>Tristan Mirault</p>
              <p>Michael J. Mirro</p>
              <p>Dinesh Mistry</p>
              <p>Nicoleta Violeta Miu</p>
              <p>Naomasa Miyamoto</p>
              <p>Tiziano Moccetti</p>
              <p>Akber Mohammed</p>
              <p>Azlisham Mohd Nor</p>
              <p>Michael Mollerus</p>
              <p>Giulio Molon</p>
              <p>Sergio Mondillo</p>
              <p>Patrícia Moniz</p>
              <p>Lluis Mont</p>
              <p>Vicente Montagud</p>
              <p>Oscar Montaña</p>
              <p>Cristina Monti</p>
              <p>Luciano Moretti</p>
              <p>Kiyoo Mori</p>
              <p>Andrew Moriarty</p>
              <p>Jacek Morka</p>
              <p>Luigi Moschini</p>
              <p>Nikitas Moschos</p>
              <p>Andreas Mügge</p>
              <p>Thomas J. Mulhearn</p>
              <p>Carmen Muresan</p>
              <p>Michela Muriago</p>
              <p>Wlodzimierz Musial</p>
              <p>Carl W. Musser</p>
              <p>Francesco Musumeci</p>
              <p>Thuraia Nageh</p>
              <p>Hidemitsu Nakagawa</p>
              <p>Yuichiro Nakamura</p>
              <p>Toru Nakayama</p>
              <p>Gi-Byoung Nam</p>
              <p>Michele Nanna</p>
              <p>Indira Natarajan</p>
              <p>Hemal M. Nayak</p>
              <p>Stefan Naydenov</p>
              <p>Jurica Nazlić</p>
              <p>Alexandru Cristian Nechita</p>
              <p>Libor Nechvatal</p>
              <p>Sandra Adela Negron</p>
              <p>James Neiman</p>
              <p>Fernando Carvalho Neuenschwander</p>
              <p>David Neves</p>
              <p>Anna Neykova</p>
              <p>Ricardo Nicolás Miguel</p>
              <p>George Nijmeh</p>
              <p>Alexey Nizov</p>
              <p>Rodrigo Noronha Campos</p>
              <p>Janko Nossan</p>
              <p>Tatiana Novikova</p>
              <p>Ewa Nowalany-Kozielska</p>
              <p>Emmanuel Nsah</p>
              <p>Juan Carlos Nunez Fragoso</p>
              <p>Svetlana Nurgalieva</p>
              <p>Dieter Nuyens</p>
              <p>Ole Nyvad</p>
              <p>Manuel Odin de Los Rios Ibarra</p>
              <p>Philip O’Donnell</p>
              <p>Martin O’Donnell</p>
              <p>Seil Oh</p>
              <p>Yong Seog Oh</p>
              <p>Dongjin Oh</p>
              <p>Gilles O’Hara</p>
              <p>Kostas Oikonomou</p>
              <p>Claudia Olivares</p>
              <p>Richard Oliver</p>
              <p>Rafael Olvera Ruiz</p>
              <p>Christoforos Olympios</p>
              <p>Anna omaszuk-Kazberuk</p>
              <p>Joaquín Osca Asensi</p>
              <p>eena Padayattil jose</p>
              <p>Francisco Gerardo Padilla Padilla</p>
              <p>Victoria Padilla Rios</p>
              <p>Giuseppe Pajes</p>
              <p>A. Shekhar Pandey</p>
              <p>Gaetano Paparella</p>
              <p>F Paris</p>
              <p>Hyung Wook Park</p>
              <p>Jong Sung Park</p>
              <p>Fragkiskos Parthenakis</p>
              <p>Enrico Passamonti</p>
              <p>Rajesh J. Patel</p>
              <p>Jaydutt Patel</p>
              <p>Mehool Patel</p>
              <p>Janice Patrick</p>
              <p>Ricardo Pavón Jimenez</p>
              <p>Analía Paz</p>
              <p>Vittorio Pengo</p>
              <p>William Pentz</p>
              <p>Beatriz Pérez</p>
              <p>Alma Minerva Pérez Ríos</p>
              <p>Alejandro Pérez-Cabezas</p>
              <p>Richard Perlman</p>
              <p>Viktor Persic</p>
              <p>Francesco Perticone</p>
              <p>Terri K. Peters</p>
              <p>Sanjiv Petkar</p>
              <p>Luis Felipe Pezo</p>
              <p>Christian Pflücke</p>
              <p>David N. Pham</p>
              <p>Roland T. Phillips</p>
              <p>Stephen Phlaum</p>
              <p>Denis Pieters</p>
              <p>Julien Pineau</p>
              <p>Arnold Pinter</p>
              <p>Fausto Pinto</p>
              <p>R. Pisters</p>
              <p>Nediljko Pivac</p>
              <p>Darko Pocanic</p>
              <p>Cristian Podoleanu</p>
              <p>Alessandro Politano</p>
              <p>Zdravka Poljakovic</p>
              <p>Stewart Pollock</p>
              <p>Jose Polo Garcéa</p>
              <p>Holger Poppert</p>
              <p>Maurizio Porcu</p>
              <p>Antonio Pose Reino</p>
              <p>Neeraj Prasad</p>
              <p>Dalton Bertolim Précoma</p>
              <p>Alessandro Prelle</p>
              <p>John Prodafikas</p>
              <p>Konstantin Protasov</p>
              <p>Maurice Pye</p>
              <p>Zhaohui Qiu</p>
              <p>Jean-Michel Quedillac</p>
              <p>Dimitar Raev</p>
              <p>Carlos Antonio Raffo Grado</p>
              <p>Sidiqullah Rahimi</p>
              <p>Arturo Raisaro</p>
              <p>Bhola Rama</p>
              <p>Ricardo Ramos</p>
              <p>Maria Ranieri</p>
              <p>Nuno Raposo</p>
              <p>Eric Rashba</p>
              <p>Ursula Rauch-Kroehnert</p>
              <p>Ramakota Reddy</p>
              <p>Giulia Renda</p>
              <p>Shabbir Reza</p>
              <p>Luigi Ria</p>
              <p>Dimitrios Richter</p>
              <p>Hans Rickli</p>
              <p>Werner Rieker</p>
              <p>Tomas Ripolil Vera</p>
              <p>Luiz Eduardo Ritt</p>
              <p>Douglas Roberts</p>
              <p>Ignacio Rodriguez Briones</p>
              <p>Aldo Edwin Rodriguez Escudero</p>
              <p>Carlos Rodríguez Pascual</p>
              <p>Mark Roman</p>
              <p>Francesco Romeo</p>
              <p>E. Ronner</p>
              <p>Jean-Francois Roux</p>
              <p>Nadezda Rozkova</p>
              <p>Miroslav Rubacek</p>
              <p>Frank Rubalcava</p>
              <p>Andrea M. Russo</p>
              <p>Matthieu Pierre Rutgers</p>
              <p>Karin Rybak</p>
              <p>Samir Said</p>
              <p>Tamotsu Sakamoto</p>
              <p>Abraham Salacata</p>
              <p>Adrien Salem</p>
              <p>Rafael Salguero Bodes</p>
              <p>Marco A. Saltzman</p>
              <p>Alessandro Salvioni</p>
              <p>Gregorio Sanchez Vallejo</p>
              <p>Marcelo Sanmartín Fernández</p>
              <p>Wladmir Faustino Saporito</p>
              <p>Kesari Sarikonda</p>
              <p>Taishi Sasaoka</p>
              <p>Hamdi Sati</p>
              <p>Irina Savelieva</p>
              <p>Pierre-Jean Scala</p>
              <p>Peter Schellinger</p>
              <p>Carlos Scherr</p>
              <p>Lisa Schmitz</p>
              <p>Karl-Heinz Schmitz</p>
              <p>Bettina Schmitz</p>
              <p>Teresa Schnabel</p>
              <p>Steffen Schnupp</p>
              <p>Peter Schoeniger</p>
              <p>Norbert Schön</p>
              <p>Peter Schwimmbeck</p>
              <p>Clare Seamark</p>
              <p>Greg Searles</p>
              <p>Karl-Heinz Seidl</p>
              <p>Barry Seidman</p>
              <p>Jaroslaw Sek</p>
              <p>Lakshmanan Sekaran</p>
              <p>Carlo Serrati</p>
              <p>Neerav Shah</p>
              <p>Vinay Shah</p>
              <p>Anil Shah</p>
              <p>Shujahat Shah</p>
              <p>Vijay Kumar Sharma</p>
              <p>Louise Shaw</p>
              <p>Khalid H. Sheikh</p>
              <p>Naruhito Shimizu</p>
              <p>Hideki Shimomura</p>
              <p>Dong-Gu Shin</p>
              <p>Eun-Seok Shin</p>
              <p>Junya Shite</p>
              <p>Gerolamo Sibilio</p>
              <p>Frank Silver</p>
              <p>Iveta Sime</p>
              <p>Tim A. Simmers</p>
              <p>Narendra Singh</p>
              <p>Peter Siostrzonek</p>
              <p>Didier Smadja</p>
              <p>David W. Smith</p>
              <p>Marcelo Snitman</p>
              <p>Dario Sobral Filho</p>
              <p>Hassan Soda</p>
              <p>Carl Sofley</p>
              <p>Adam Sokal</p>
              <p>Yannie Soo Oi Yan</p>
              <p>Rodolfo Sotolongo</p>
              <p>Olga Ferreira de Souza</p>
              <p>Jon Arne Sparby</p>
              <p>Jindrich Spinar</p>
              <p>David Sprigings</p>
              <p>Alex C. Spyropoulos</p>
              <p>Dimitrios Stakos</p>
              <p>Clemens Steinwender</p>
              <p>Georgios Stergiou</p>
              <p>Ian Stiell</p>
              <p>Marcus Stoddard</p>
              <p>Anastas Stoikov</p>
              <p>Witold Streb</p>
              <p>Ioannis Styliadis</p>
              <p>Guohai Su</p>
              <p>Xi Su</p>
              <p>Wanda Sudnik</p>
              <p>Kai Sukles</p>
              <p>Xiaofei Sun</p>
              <p>H. Swart</p>
              <p>Janko Szavits-Nossan</p>
              <p>Jens Taggeselle</p>
              <p>Yuichiro Takagi</p>
              <p>Amrit Pal Singh Takhar</p>
              <p>Angelika Tamm</p>
              <p>Katsumi Tanaka</p>
              <p>Tanyanan Tanawuttiwat</p>
              <p>Sherman Tang</p>
              <p>Aylmer Tang</p>
              <p>Giovanni Tarsi</p>
              <p>Tiziana Tassinari</p>
              <p>Ashis Tayal</p>
              <p>Muzahir Tayebjee</p>
              <p>J.M. ten Berg</p>
              <p>Dan Tesloianu</p>
              <p>Salem H.K. The</p>
              <p>Dierk Thomas</p>
              <p>Serge Timsit</p>
              <p>Tetsuya Tobaru</p>
              <p>Andrzej R. Tomasik.</p>
              <p>Mikhail Torosoff</p>
              <p>Emmanuel Touze</p>
              <p>Elina Trendafilova</p>
              <p>W. Kevin Tsai</p>
              <p>Hung Fat Tse</p>
              <p>Hiroshi Tsutsui</p>
              <p>Tian Ming Tu</p>
              <p>Ype Tuininga</p>
              <p>Minang Turakhia</p>
              <p>Samir Turk</p>
              <p>Wayne Turner</p>
              <p>Arnljot Tveit</p>
              <p>Richard Tytus</p>
              <p>C Valadão</p>
              <p>P.F.M.M. van Bergen</p>
              <p>Philippe van de Borne</p>
              <p>B.J. van den Berg</p>
              <p>C van der Zwaan</p>
              <p>M. Van Eck</p>
              <p>Peter Vanacker</p>
              <p>Dimo Vasilev</p>
              <p>Vasileios Vasilikos</p>
              <p>Maxim Vasilyev</p>
              <p>Srikar Veerareddy</p>
              <p>Mario Vega Miño</p>
              <p>Asok Venkataraman</p>
              <p>Paolo Verdecchia</p>
              <p>Francesco Versaci</p>
              <p>Ernst Günter Vester</p>
              <p>Hubert Vial</p>
              <p>Jason Victory</p>
              <p>Alejandro Villamil</p>
              <p>Marc Vincent</p>
              <p>Anthony Vlastaris</p>
              <p>Jürgen vom Dahl</p>
              <p>Kishor Vora</p>
              <p>Robert B. Vranian</p>
              <p>Paul Wakefield</p>
              <p>Ningfu Wang</p>
              <p>Mingsheng Wang</p>
              <p>Xinhua Wang</p>
              <p>Feng Wang</p>
              <p>Tian Wang</p>
              <p>Alberta L. Warner</p>
              <p>Kouki Watanabe</p>
              <p>Jeanne Wei</p>
              <p>Christian Weimar</p>
              <p>Stanislav Weiner</p>
              <p>Renate Weinrich</p>
              <p>Ming-Shien Wen</p>
              <p>Marcus Wiemer</p>
              <p>Preben Wiggers</p>
              <p>Andreas Wilke</p>
              <p>David Williams</p>
              <p>Marcus L. Williams</p>
              <p>Bernhard Witzenbichler</p>
              <p>Brian Wong</p>
              <p>Ka Sing Lawrence Wong</p>
              <p>Beata Wozakowska-Kaplon</p>
              <p>Shulin Wu</p>
              <p>Richard C. Wu</p>
              <p>Silke Wunderlich</p>
              <p>Nell Wyatt</p>
              <p>John (Jack) Wylie</p>
              <p>Yong Xu</p>
              <p>Xiangdong Xu</p>
              <p>Hiroki Yamanoue</p>
              <p>Takeshi Yamashita</p>
              <p>Ping Yen Bryan Yan</p>
              <p>Tianlun Yang</p>
              <p>Jing Yao</p>
              <p>Kuo-Ho Yeh</p>
              <p>Wei Hsian Yin</p>
              <p>Yoto Yotov</p>
              <p>Ralf Zahn</p>
              <p>Stuart Zarich</p>
              <p>Sergei Zenin</p>
              <p>Elisabeth Louise Zeuthen</p>
              <p>Huanyi Zhang</p>
              <p>Donghui Zhang</p>
              <p>Xingwei Zhang</p>
              <p>Ping Zhang</p>
              <p>Jun Zhang</p>
              <p>Shui Ping Zhao</p>
              <p>Yujie Zhao</p>
              <p>Zhichen Zhao</p>
              <p>Yang Zheng</p>
              <p>Jing Zhou</p>
              <p>Sergio Zimmermann</p>
              <p>Andrea Zini</p>
              <p>Steven Zizzo</p>
              <p>Wenxia Zong</p>
              <p>L Steven Zukerman</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pone.0249524.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Haim</surname><given-names>M</given-names></name>, <name><surname>Hoshen</surname><given-names>M</given-names></name>, <name><surname>Reges</surname><given-names>O</given-names></name>, <name><surname>Rabi</surname><given-names>Y</given-names></name>, <name><surname>Balicer</surname><given-names>R</given-names></name>, <name><surname>Leibowitz</surname><given-names>M</given-names></name>. <article-title>Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation</article-title>. <source>J Am Heart Assoc</source>. <year>2015</year>;<volume>4</volume>(<issue>1</issue>):<fpage>e001486</fpage>. <pub-id pub-id-type="doi">10.1161/JAHA.114.001486</pub-id><?supplied-pmid 25609415?><pub-id pub-id-type="pmid">25609415</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Rahman</surname><given-names>F</given-names></name>, <name><surname>Kwan</surname><given-names>GF</given-names></name>, <name><surname>Benjamin</surname><given-names>EJ</given-names></name>. <article-title>Global epidemiology of atrial fibrillation</article-title>. <source>Nat Rev Cardiol</source>. <year>2014</year>;<volume>11</volume>(<issue>11</issue>):<fpage>639</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1038/nrcardio.2014.118</pub-id>
<?supplied-pmid 25113750?><pub-id pub-id-type="pmid">25113750</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>LaMori</surname><given-names>JC</given-names></name>, <name><surname>Mody</surname><given-names>SH</given-names></name>, <name><surname>Gross</surname><given-names>HJ</given-names></name>, <name><surname>daCosta DiBonaventura</surname><given-names>M</given-names></name>, <name><surname>Patel</surname><given-names>AA</given-names></name>, <name><surname>Schein</surname><given-names>JR</given-names></name>, <etal>et al</etal>. <article-title>Burden of comorbidities among patients with atrial fibrillation</article-title>. <source>Ther Adv Cardiovasc Dis</source>. <year>2013</year>;<volume>7</volume>(<issue>2</issue>):<fpage>53</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1177/1753944712464101</pub-id>
<?supplied-pmid 23090783?><pub-id pub-id-type="pmid">23090783</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Boyd</surname><given-names>CM</given-names></name>, <name><surname>Fortin</surname><given-names>M</given-names></name>. <article-title>Future of Multimorbidity Research: How Should Understanding of Multimorbidity Inform Health System Design?</article-title><source>Public Health Reviews</source>. <year>2010</year>;<volume>32</volume>(<issue>2</issue>):<fpage>451</fpage>–<lpage>74</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0249524.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Barnett</surname><given-names>K</given-names></name>, <name><surname>Mercer</surname><given-names>SW</given-names></name>, <name><surname>Norbury</surname><given-names>M</given-names></name>, <name><surname>Watt</surname><given-names>G</given-names></name>, <name><surname>Wyke</surname><given-names>S</given-names></name>, <name><surname>Guthrie</surname><given-names>B</given-names></name>. <article-title>Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>380</volume>(<issue>9836</issue>):<fpage>37</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(12)60240-2</pub-id>
<?supplied-pmid 22579043?><pub-id pub-id-type="pmid">22579043</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Coleman</surname><given-names>CI</given-names></name>, <name><surname>Antz</surname><given-names>M</given-names></name>, <name><surname>Bowrin</surname><given-names>K</given-names></name>, <name><surname>Evers</surname><given-names>T</given-names></name>, <name><surname>Simard</surname><given-names>EP</given-names></name>, <name><surname>Bonnemeier</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study</article-title>. <source>Curr Med Res Opin</source>. <year>2016</year>;<volume>32</volume>(<issue>12</issue>):<fpage>2047</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1080/03007995.2016.1237937</pub-id>
<?supplied-pmid 27633045?><pub-id pub-id-type="pmid">27633045</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Lip</surname><given-names>G</given-names></name>, <name><surname>Freedman</surname><given-names>B</given-names></name>, <name><surname>De Caterina</surname><given-names>R</given-names></name>, <name><surname>Potpara</surname><given-names>TS</given-names></name>. <article-title>Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making</article-title>. <source>Thromb Haemost</source>. <year>2017</year>;<volume>117</volume>(<issue>7</issue>):<fpage>1230</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1160/TH16-11-0876</pub-id>
<?supplied-pmid 28597905?><pub-id pub-id-type="pmid">28597905</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Huisman</surname><given-names>MV</given-names></name>, <name><surname>Lip</surname><given-names>GY</given-names></name>, <name><surname>Diener</surname><given-names>HC</given-names></name>, <name><surname>Dubner</surname><given-names>SJ</given-names></name>, <name><surname>Halperin</surname><given-names>JL</given-names></name>, <name><surname>Ma</surname><given-names>CS</given-names></name>, <etal>et al</etal>. <article-title>Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation</article-title>. <source>Am Heart J</source>. <year>2014</year>;<volume>167</volume>(<issue>3</issue>):<fpage>329</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.ahj.2013.12.006</pub-id>
<?supplied-pmid 24576516?><pub-id pub-id-type="pmid">24576516</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Lip</surname><given-names>GY</given-names></name>, <name><surname>Nieuwlaat</surname><given-names>R</given-names></name>, <name><surname>Pisters</surname><given-names>R</given-names></name>, <name><surname>Lane</surname><given-names>DA</given-names></name>, <name><surname>Crijns</surname><given-names>HJ</given-names></name>. <article-title>Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation</article-title>. <source>Chest</source>. <year>2010</year>;<volume>137</volume>(<issue>2</issue>):<fpage>263</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1378/chest.09-1584</pub-id>
<?supplied-pmid 19762550?><pub-id pub-id-type="pmid">19762550</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Pisters</surname><given-names>R</given-names></name>, <name><surname>Lane</surname><given-names>DA</given-names></name>, <name><surname>Nieuwlaat</surname><given-names>R</given-names></name>, <name><surname>de Vos</surname><given-names>CB</given-names></name>, <name><surname>Crijns</surname><given-names>HJ</given-names></name>, <name><surname>Lip</surname><given-names>GY</given-names></name>. <article-title>A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey</article-title>. <source>Chest</source>. <year>2010</year>;<volume>138</volume>(<issue>5</issue>):<fpage>1093</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1378/chest.10-0134</pub-id>
<?supplied-pmid 20299623?><pub-id pub-id-type="pmid">20299623</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Austin</surname><given-names>PC</given-names></name>. <article-title>Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research</article-title>. <source>Communications in Statistics—Simulation and Computation</source>. <year>2009</year>;<volume>38</volume>(<issue>6</issue>):<fpage>1228</fpage>–<lpage>34</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0249524.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>White</surname><given-names>IR</given-names></name>, <name><surname>Royston</surname><given-names>P</given-names></name>, <name><surname>Wood</surname><given-names>AM</given-names></name>. <article-title>Multiple imputation using chained equations: Issues and guidance for practice</article-title>. <source>Stat Med</source>. <year>2011</year>;<volume>30</volume>(<issue>4</issue>):<fpage>377</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1002/sim.4067</pub-id>
<?supplied-pmid 21225900?><pub-id pub-id-type="pmid">21225900</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Boriani</surname><given-names>G</given-names></name>, <name><surname>Proietti</surname><given-names>M</given-names></name>, <name><surname>Laroche</surname><given-names>C</given-names></name>, <name><surname>Fauchier</surname><given-names>L</given-names></name>, <name><surname>Marin</surname><given-names>F</given-names></name>, <name><surname>Nabauer</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry</article-title>. <source>Europace</source>. <year>2018</year>;<volume>20</volume>(<issue>5</issue>):<fpage>747</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1093/europace/eux301</pub-id>
<?supplied-pmid 29016832?><pub-id pub-id-type="pmid">29016832</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Steinberg</surname><given-names>BA</given-names></name>, <name><surname>Shrader</surname><given-names>P</given-names></name>, <name><surname>Thomas</surname><given-names>L</given-names></name>, <name><surname>Ansell</surname><given-names>J</given-names></name>, <name><surname>Fonarow</surname><given-names>GC</given-names></name>, <name><surname>Gersh</surname><given-names>BJ</given-names></name>, <etal>et al</etal>. <article-title>Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)</article-title>. <source>Am Heart J</source>. <year>2017</year>;<volume>189</volume>:<fpage>40</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.ahj.2017.03.024</pub-id>
<?supplied-pmid 28625380?><pub-id pub-id-type="pmid">28625380</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Proietti</surname><given-names>M</given-names></name>, <name><surname>Marzona</surname><given-names>I</given-names></name>, <name><surname>Vannini</surname><given-names>T</given-names></name>, <name><surname>Tettamanti</surname><given-names>M</given-names></name>, <name><surname>Fortino</surname><given-names>I</given-names></name>, <name><surname>Merlino</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use</article-title>. <source>Mayo Clin Proc</source>. <year>2019</year>;<volume>94</volume>(<issue>12</issue>):<fpage>2427</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.mayocp.2019.06.012</pub-id>
<?supplied-pmid 31668449?><pub-id pub-id-type="pmid">31668449</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Connolly</surname><given-names>SJ</given-names></name>, <name><surname>Pogue</surname><given-names>J</given-names></name>, <name><surname>Hart</surname><given-names>RG</given-names></name>, <name><surname>Hohnloser</surname><given-names>SH</given-names></name>, <name><surname>Pfeffer</surname><given-names>M</given-names></name>, <name><surname>Chrolavicius</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Effect of clopidogrel added to aspirin in patients with atrial fibrillation</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>20</issue>):<fpage>2066</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0901301</pub-id>
<?supplied-pmid 19336502?><pub-id pub-id-type="pmid">19336502</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Proietti</surname><given-names>M</given-names></name>, <name><surname>Laroche</surname><given-names>C</given-names></name>, <name><surname>Opolski</surname><given-names>G</given-names></name>, <name><surname>Maggioni</surname><given-names>AP</given-names></name>, <name><surname>Boriani</surname><given-names>G</given-names></name>, <name><surname>Lip</surname><given-names>GYH</given-names></name>, <etal>et al</etal>. <article-title>‘Real-world’ atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase</article-title>. <source>EP Europace</source>. <year>2016</year>;<volume>19</volume>(<issue>5</issue>):<fpage>722</fpage>–<lpage>33</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0249524.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Lip</surname><given-names>GY</given-names></name>, <name><surname>Laroche</surname><given-names>C</given-names></name>, <name><surname>Dan</surname><given-names>GA</given-names></name>, <name><surname>Santini</surname><given-names>M</given-names></name>, <name><surname>Kalarus</surname><given-names>Z</given-names></name>, <name><surname>Rasmussen</surname><given-names>LH</given-names></name>, <etal>et al</etal>. <article-title>’Real-world’ antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey</article-title>. <source>Am J Med</source>. <year>2014</year>;<volume>127</volume>(<issue>6</issue>):<fpage>519</fpage>–<lpage>29.e1</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjmed.2013.12.022</pub-id>
<?supplied-pmid 24486284?><pub-id pub-id-type="pmid">24486284</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Lip</surname><given-names>GYH</given-names></name>, <name><surname>Banerjee</surname><given-names>A</given-names></name>, <name><surname>Boriani</surname><given-names>G</given-names></name>, <name><surname>Chiang</surname><given-names>CE</given-names></name>, <name><surname>Fargo</surname><given-names>R</given-names></name>, <name><surname>Freedman</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report</article-title>. <source>Chest</source>. <year>2018</year>;<volume>154</volume>(<issue>5</issue>):<fpage>1121</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2018.07.040</pub-id>
<?supplied-pmid 30144419?><pub-id pub-id-type="pmid">30144419</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Wilke</surname><given-names>T</given-names></name>, <name><surname>Groth</surname><given-names>A</given-names></name>, <name><surname>Mueller</surname><given-names>S</given-names></name>, <name><surname>Pfannkuche</surname><given-names>M</given-names></name>, <name><surname>Verheyen</surname><given-names>F</given-names></name>, <name><surname>Linder</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients</article-title>. <source>Thromb Haemost</source>. <year>2012</year>;<volume>107</volume>(<issue>6</issue>):<fpage>1053</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1160/TH11-11-0768</pub-id>
<?supplied-pmid 22398417?><pub-id pub-id-type="pmid">22398417</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Kirchhof</surname><given-names>P</given-names></name>, <name><surname>Benussi</surname><given-names>S</given-names></name>, <name><surname>Kotecha</surname><given-names>D</given-names></name>, <name><surname>Ahlsson</surname><given-names>A</given-names></name>, <name><surname>Atar</surname><given-names>D</given-names></name>, <name><surname>Casadei</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS</article-title>. <source>Eur Heart J</source>. <year>2016</year>;<volume>37</volume>(<issue>38</issue>):<fpage>2893</fpage>–<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehw210</pub-id>
<?supplied-pmid 27567408?><pub-id pub-id-type="pmid">27567408</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Boriani</surname><given-names>G</given-names></name>, <name><surname>Proietti</surname><given-names>M</given-names></name>, <name><surname>Laroche</surname><given-names>C</given-names></name>, <name><surname>Fauchier</surname><given-names>L</given-names></name>, <name><surname>Marin</surname><given-names>F</given-names></name>, <name><surname>Nabauer</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry</article-title>. <source>Europace</source>. <year>2018</year>;<volume>20</volume>(<issue>5</issue>):<fpage>747</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1093/europace/eux301</pub-id>
<?supplied-pmid 29016832?><pub-id pub-id-type="pmid">29016832</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Scowcroft</surname><given-names>AC</given-names></name>, <name><surname>Lee</surname><given-names>S</given-names></name>, <name><surname>Mant</surname><given-names>J</given-names></name>. <article-title>Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000–2009</article-title>. <source>Heart</source>. <year>2013</year>;<volume>99</volume>(<issue>2</issue>):<fpage>127</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1136/heartjnl-2012-302843</pub-id>
<?supplied-pmid 23086966?><pub-id pub-id-type="pmid">23086966</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Chan</surname><given-names>PS</given-names></name>, <name><surname>Maddox</surname><given-names>TM</given-names></name>, <name><surname>Tang</surname><given-names>F</given-names></name>, <name><surname>Spinler</surname><given-names>S</given-names></name>, <name><surname>Spertus</surname><given-names>JA</given-names></name>. <article-title>Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program)</article-title>. <source>Am J Cardiol</source>. <year>2011</year>;<volume>108</volume>(<issue>8</issue>):<fpage>1136</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2011.06.017</pub-id>
<?supplied-pmid 21798501?><pub-id pub-id-type="pmid">21798501</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>van Walraven</surname><given-names>C</given-names></name>, <name><surname>Hart</surname><given-names>RG</given-names></name>, <name><surname>Connolly</surname><given-names>S</given-names></name>, <name><surname>Austin</surname><given-names>PC</given-names></name>, <name><surname>Mant</surname><given-names>J</given-names></name>, <name><surname>Hobbs</surname><given-names>FD</given-names></name>, <etal>et al</etal>. <article-title>Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators</article-title>. <source>Stroke</source>. <year>2009</year>;<volume>40</volume>(<issue>4</issue>):<fpage>1410</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1161/STROKEAHA.108.526988</pub-id>
<?supplied-pmid 19182090?><pub-id pub-id-type="pmid">19182090</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Vanbeselaere</surname><given-names>V</given-names></name>, <name><surname>Truyers</surname><given-names>C</given-names></name>, <name><surname>Elli</surname><given-names>S</given-names></name>, <name><surname>Buntinx</surname><given-names>F</given-names></name>, <name><surname>De Witte</surname><given-names>H</given-names></name>, <name><surname>Degryse</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Association between atrial fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a registry-based study</article-title>. <source>BMC Cardiovasc Disord</source>. <year>2016</year>;<volume>16</volume>:<fpage>61</fpage>. <pub-id pub-id-type="doi">10.1186/s12872-016-0235-1</pub-id><?supplied-pmid 27021333?><pub-id pub-id-type="pmid">27021333</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Steffel</surname><given-names>J</given-names></name>, <name><surname>Verhamme</surname><given-names>P</given-names></name>, <name><surname>Potpara</surname><given-names>TS</given-names></name>, <name><surname>Albaladejo</surname><given-names>P</given-names></name>, <name><surname>Antz</surname><given-names>M</given-names></name>, <name><surname>Desteghe</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</article-title>. <source>Eur Heart J</source>. <year>2018</year>;<volume>39</volume>(<issue>16</issue>):<fpage>1330</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehy136</pub-id>
<?supplied-pmid 29562325?><pub-id pub-id-type="pmid">29562325</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Friberg</surname><given-names>L</given-names></name>, <name><surname>Hammar</surname><given-names>N</given-names></name>, <name><surname>Rosenqvist</surname><given-names>M</given-names></name>. <article-title>Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation</article-title>. <source>Eur Heart J</source>. <year>2010</year>;<volume>31</volume>(<issue>8</issue>):<fpage>967</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehn599</pub-id>
<?supplied-pmid 19176537?><pub-id pub-id-type="pmid">19176537</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0249524.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Fumagalli</surname><given-names>S</given-names></name>, <name><surname>Said</surname><given-names>SA</given-names></name>, <name><surname>Laroche</surname><given-names>C</given-names></name>, <name><surname>Gabbai</surname><given-names>D</given-names></name>, <name><surname>Boni</surname><given-names>S</given-names></name>, <name><surname>Marchionni</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report</article-title>. <source>European Heart Journal—Cardiovascular Pharmacotherapy</source>. <year>2017</year>;<volume>4</volume>(<issue>3</issue>):<fpage>172</fpage>–<lpage>9</lpage>.</mixed-citation>
              </ref>
              <ref id="pone.0249524.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Chiang</surname><given-names>CE</given-names></name>, <name><surname>Wang</surname><given-names>KL</given-names></name>, <name><surname>Lip</surname><given-names>GY</given-names></name>. <article-title>Stroke prevention in atrial fibrillation: an Asian perspective</article-title>. <source>Thromb Haemost</source>. <year>2014</year>;<volume>111</volume>(<issue>5</issue>):<fpage>789</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1160/TH13-11-0948</pub-id>
<?supplied-pmid 24500243?><pub-id pub-id-type="pmid">24500243</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <sub-article id="pone.0249524.r001" article-type="aggregated-review-documents">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0249524.r001</article-id>
              <title-group>
                <article-title>Decision Letter 0</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Garcia de Frutos</surname>
                    <given-names>Pablo</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Pablo Garcia de Frutos</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Pablo Garcia de Frutos</copyright-holder>
                <license>
                  <ali:license_ref specific-use="pmc" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj001" ext-link-type="doi" xlink:href="10.1371/journal.pone.0249524" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>0</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">25 Jan 2021</named-content>
              </p>
              <p>PONE-D-20-40256</p>
              <p>Manuscript Type: Original article</p>
              <p>Atrial Fibrillation and Comorbidities: Clinical Characteristics and Antithrombotic Treatment in GLORIA-AF</p>
              <p>PLOS ONE</p>
              <p>Dear Dr. Kozieł,</p>
              <p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
              <p>The study has been revised by two academics, with expertise in the field of the study and its statatistical methods. The methodology employed is partly correct and sound in general, as assessed by the reviewers. However, there are some specific aspects of the statistical methods used that should be revised/clarified. One point is the type of treatment that the individuals are employing. If the treatment changes, the authors should indicate how they account for this change in their model. A reorganization of the manuscript, to a certain extent, is suggested by one reviewer in the attached document, aiming at a more understandable presentation of the data. Further, the reviewer recommends including a further discussion/comparison with recent data on different cohorts.</p>
              <p>Please submit your revised manuscript by Mar 07 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link ext-link-type="uri" xlink:href="https://www.editorialmanager.com/pone/">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
              <p>Please include the following items when submitting your revised manuscript:</p>
              <p>
                <list list-type="bullet">
                  <list-item>
                    <p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
                  </list-item>
                  <list-item>
                    <p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
                  </list-item>
                  <list-item>
                    <p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
                  </list-item>
                </list>
              </p>
              <p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
              <p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" xlink:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link></p>
              <p>We look forward to receiving your revised manuscript.</p>
              <p>Kind regards,</p>
              <p>Pablo Garcia de Frutos</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Journal Requirements:</p>
              <p>When submitting your revision, we need you to address these additional requirements.</p>
              <p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
              <p><ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p>
              <p>
                <ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
              </p>
              <p>2. Thank you for submitting your clinical trial to PLOS ONE and for providing the name of the registry and the registration number. The information in the registry entry suggests that your trial was registered after patient recruitment began. PLOS ONE strongly encourages authors to register all trials before recruiting the first participant in a study.</p>
              <p>As per the journal’s editorial policy, please include in the Methods section of your paper:</p>
              <p>1) your reasons for your delay in registering this study (after enrolment of participants started);</p>
              <p>2) confirmation that all related trials are registered by stating: “The authors confirm that all ongoing and related trials for this drug/intervention are registered”.</p>
              <p>3. Thank you for stating the following in the Competing Interests section:</p>
              <p>"Dr Kozieł and Professor Rothman declare no conflicts of interest.</p>
              <p>Dr Teutsch, Dr Lu, Sabrina Marler, and Venkatesh K. Gurusamy are employees of Boehringer Ingelheim.</p>
              <p>Professor Halperin has engaged in consulting activities for Boehringer Ingelheim and advisory activities involving anticoagulants, and he is a member of the Executive Steering Committee of the GLORIA-AF Registry.</p>
              <p>Over the past 3 years, Professor Diener received honoraria for participation in clinical trials, contribution to advisory boards, or oral presentations from: Abbott, Bayer Vital, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Pfizer, Portola, Sanofi-Aventis, and WebMD Global. Financial support for research projects was provided by Boehringer Ingelheim. He received research grants from the German Research Council (DFG), German Ministry of Education and Research (BMBF), European Union, NIH, Bertelsmann Foundation, and Heinz-Nixdorf Foundation.</p>
              <p>Professor Ma received honoraria from Bristol-Myers Squibb, Pfizer, Johnson &amp; Johnson, Boehringer Ingelheim, Bayer, and AstraZeneca for giving lectures.</p>
              <p>Professor Huisman reports grants from ZonMW Dutch Healthcare Fund, grants and personal fees from Boehringer Ingelheim, Pfizer/Bristol-Myers Squibb, Bayer Health Care, Aspen, Daiichi Sankyo, outside the submitted work.</p>
              <p>Professor Lip has been a consultant for Bayer/Janssen, Bristol-Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi Sankyo. He has been a speaker for Bayer, Bristol-Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi Sankyo. No fees directly received personally."</p>
              <p>We note that one or more of the authors have an affiliation to the commercial funders of this research study : Boehringer Ingelheim. We also note that one or more of the authors are employed by a commercial company: RTI Health Solutions.</p>
              <p>3.1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.</p>
              <p>Please also include the following statement within your amended Funding Statement.</p>
              <p>“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.”</p>
              <p>If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.</p>
              <p>3.2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  </p>
              <p>Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors <ext-link ext-link-type="uri" xlink:href="about:blank">http://journals.plos.org/plosone/s/competing-interests</ext-link>). If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.</p>
              <p>Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.</p>
              <p>Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <ext-link ext-link-type="uri" xlink:href="about:blank">http://journals.plos.org/plosone/s/competing-interests</ext-link></p>
              <p>4. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.</p>
              <p>5. Please amend either the title on the online submission form (via Edit Submission) or the title in the manuscript so that they are identical.</p>
              <p>6. One of the noted authors is a group or consortium [GLORIA-AF Investigators]. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address.</p>
              <p>7. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <ext-link ext-link-type="uri" xlink:href="about:blank">http://journals.plos.org/plosone/s/supporting-information</ext-link>.</p>
              <p>[Note: HTML markup is below. Please do not edit.]</p>
              <p>Reviewers' comments:</p>
              <p>Reviewer's Responses to Questions</p>
              <p>
                <bold>Comments to the Author</bold>
              </p>
              <p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
              <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Partly</p>
              <p>**********</p>
              <p>2. Has the statistical analysis been performed appropriately and rigorously? </p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: No</p>
              <p>**********</p>
              <p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
              <p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: No</p>
              <p>**********</p>
              <p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
              <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>5. Review Comments to the Author</p>
              <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
              <p>Reviewer #1: The authors of the paper “Atrial Fibrillation and Comorbidities: Clinical Characteristics and Antithrombotic Treatment in GLORIA-AF" have been focused on the analysis objective, specifically in baseline characteristics and antithrombotic therapy in patients with AF and more than two concomitant and chronic comorbidities.</p>
              <p>For more information, please check the attached file.</p>
              <p>Reviewer #2: PONE-D-20-40256: statistical review</p>
              <p>SUMMARY. This study describes factors that are associated with oral anticoagulant (OAC) prescription in subjects with atrial fibrillation and comorbidities. I am not sure that the association between patient's characteristics and prescription makes sense as a research question. However, I'm not a medical doctor and I am going to limit my discussion to the statistical methods that are deployed here.</p>
              <p>From a statistical viewpoint, the core of the analysis relies on a cross-sectional log-binomial regression model, estimated by likelihood-based multiple imputation methods. These methods could in principle be appropriate, but the paper lacks information about the data structure and the multiple imputation method. I therefore need to ask first some questions (major issues 1 and 2 below) before making a recommendation.</p>
              <p>MAJOR ISSUES</p>
              <p>1. Little is said about the structure of the response variable: OAC prescriptions. The cross-sectional log-binomial regression model assumes that the response variable is a binary variable. It therefore makes sense if each subject receive only one type of prescription during the whole follow up. In this case, the model chosen provides a correct approach. If instead subjects switch between a type of prescription to another one, then this method is no longer correct and the data must be examined by a longitudinal version of the model that includes subject-specific random effects. Please clarify.</p>
              <p>2. The authors correctly use multiple imputation to handle missing data in a regression framework. However, nothing is said about the model used to generate the imputation sample. If all the incomplete covariates are continuous, a multivariate normal distribution is typically used for imputation. However, in this study, incomplete covariates are of mixed type (some are continuous, others are categorical). I therefore wonder what model has been used at the imputation step.</p>
              <p>**********</p>
              <p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
              <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
              <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy">Privacy Policy</ext-link>.</p>
              <p>Reviewer #1: No</p>
              <p>Reviewer #2: No</p>
              <p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
              <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" xlink:href="https://pacev2.apexcovantage.com/">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
              <supplementary-material content-type="local-data" id="pone.0249524.s003">
                <label>Attachment</label>
                <caption>
                  <p>Submitted filename: <named-content content-type="submitted-filename">Gloria-AF registry,.pdf</named-content></p>
                </caption>
                <media xlink:href="pone.0249524.s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </body>
          </sub-article>
          <sub-article id="pone.0249524.r002" article-type="author-comment">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0249524.r002</article-id>
              <title-group>
                <article-title>Author response to Decision Letter 0</article-title>
              </title-group>
              <related-article id="rel-obj002" ext-link-type="doi" xlink:href="10.1371/journal.pone.0249524" related-article-type="editor-report"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="author-response-date">4 Mar 2021</named-content>
              </p>
              <p>Reviewer #1</p>
              <p>The authors of the paper “Atrial Fibrillation and Comorbidities: Clinical Characteristics and Antithrombotic Treatment in GLORIA-AF" have been focused on the analysis objective, specifically in baseline characteristics and antithrombotic therapy in patients with AF and more than two concomitant and chronic comorbidities. Authors have done, through Gloria-AF registry, an international covered registry, a genuine work in screening of baseline characteristics and medication of an enormous number of patients with AF during a three-year enrolling period. Even though we have the baseline picture, it is of a big interest to know the trend or changes with regards to oral anticoagulation (OAC) therapy during the follow-up (FU), but as mentioned in Limitations the authors have chosen to show the FU data probably later on. General comments: The manuscript is well written with the objective and methodology clearly described. The authors make an important point showing that patients with AF and a high-risk profile for stroke, more than 2 chronic comorbidities, were unfortunately undertreated with NOAC, in a period when at least three NOACs were established in the clinical use. According to the authors, around 60% of those patients were on NOAC regimen, but still 16% of those patients were without OAC, despite CHA2DS2-VASc ≥ 2. This work points the fact that younger patients with AF and less comorbidities were likely to were on NOAC regimen, at the same time that observations and clinical practice today show something different. In this perspective, I think it is very important the future information from the registry if the trends during the follow-up will show the impact of implementation of the current guidelines for the antithrombotic therapy in patients with AF. I have some comments I would like to address to the authors: </p>
              <p>1. I will appreciate if the authors can explain or argue what was the reason for choosing of standardized differences in order to compare baseline characteristics between different stroke prevention strategies.</p>
              <p>Authors’ response:</p>
              <p>Thank you. Standardized differences were used because they are independent of sample size and it allows for the comparison of the relative balance of variables measured in different units. </p>
              <p> 2. Again, when considering the trend aspect, it is of interest if a trend of increased NOAC use was observed during the last year of inclusion as compared with the previous year(s).</p>
              <p>Authors’ response:</p>
              <p>Thank you. Trends of NOAC use during the last years of inclusion as compared with previous years has been addressed by a different manuscript which has been under separate development for submission. </p>
              <p> 3. In Discussion, I feel sometimes that authors give some more results rather than discuss the findings and face them with the literature, and specifically in the second paragraph.</p>
              <p>Authors’ response:</p>
              <p>Thank you. The Discussion has been edited and the findings have been discussed along with other studies (see pages 8-12).</p>
              <p>4. I miss the comparison and discussion with some more recent findings regarding to NOAC use, where data from Scandinavia has given a different picture than probably other regions in Europe. </p>
              <p>Authors’ response:</p>
              <p>Thank you. Our findings have been compared and discussed with Scandinavian registries regarding NOAC (see pages 11 and 12). </p>
              <p>‘Of note, younger patients (18-54 years) and ≥75 years were less likely to receive NOAC than those aged 65-74 years in Sweden (31). In Denmark, older age was associated with increased NOAC use (32).’</p>
              <p>‘In contrast, HF was associated with decreased OAC initiation in Danish dataset (33).’</p>
              <p>‘In Danish nationwide registries, bleeding was also associated with decreased OAC use (33).’</p>
              <p>‘In our registry, previous TIA or stroke was the comorbidity associated with decreased VKA use in multimorbid AF patients in Europe. Interestingly, stroke/ thromboembolism or bleeding were associated with increased NOAC initiation in Denmark (32)’.</p>
              <p>5. The tables are informative and presented well, but sometimes the perception of overflow is not avoidable. The possibility to cut some information could be considered. </p>
              <p>Authors’ response:</p>
              <p>Thank you. The tables have been carefully revised and some excessive information has been deleted (see Tables 2-5). </p>
              <p>6. I would like to have in the ordinary tables one of those included in supplements, specifically table S3 and would recommend authors to change with another one. I believe that one of strengths with this analysis is the region-specific patients enrolling and comparisons.</p>
              <p>Authors’ response:</p>
              <p>Thank you. The Table S3 have been changed into separate tables for Asia, Europe, North America and South America (see Table S3, S4, S5 and S6). </p>
              <p>Reviewer #2: PONE-D-20-40256: statistical review</p>
              <p>SUMMARY. This study describes factors that are associated with oral anticoagulant (OAC) prescription in subjects with atrial fibrillation and comorbidities. I am not sure that the association between patient's characteristics and prescription makes sense as a research question. However, I'm not a medical doctor and I am going to limit my discussion to the statistical methods that are deployed here.</p>
              <p>From a statistical viewpoint, the core of the analysis relies on a cross-sectional log-binomial regression model, estimated by likelihood-based multiple imputation methods. These methods could in principle be appropriate, but the paper lacks information about the data structure and the multiple imputation method. I therefore need to ask first some questions (major issues 1 and 2 below) before making a recommendation.</p>
              <p>MAJOR ISSUES</p>
              <p>1. Little is said about the structure of the response variable: OAC prescriptions. The cross-sectional log-binomial regression model assumes that the response variable is a binary variable. It therefore makes sense if each subject receive only one type of prescription during the whole follow up. In this case, the model chosen provides a correct approach. If instead subjects switch between a type of prescription to another one, then this method is no longer correct and the data must be examined by a longitudinal version of the model that includes subject-specific random effects. Please clarify.</p>
              <p>Authors’ response:</p>
              <p>Thank you. In this registry, there was no intervention in treatment prescription for patients over time, so patients can have more than one types of treatment prescribed during the study. The cross-sectional association analysis is based on the first prescription of antithrombotic treatment (i.e. index treatment) that was prescribed as long term use at baseline visit. Per inclusion criteria in protocol, the patients enrolled in the study must have been newly diagnosed (&lt;3 months prior to baseline visit) with non-valvular AF. In order to clarify this definition of response variable in the manuscript, we have changed ‘OAC prescription’ to ‘baseline OAC prescription’. </p>
              <p>2. The authors correctly use multiple imputation to handle missing data in a regression framework. However, nothing is said about the model used to generate the imputation sample. If all the incomplete covariates are continuous, a multivariate normal distribution is typically used for imputation. However, in this study, incomplete covariates are of mixed type (some are continuous, others are categorical). I therefore wonder what model has been used at the imputation step.</p>
              <p>Authors’ response:</p>
              <p>Thank you. The technique called multiple imputation by chained equations or fully conditional specification) was used to impute missing continuous and categorical variables. This method was well described in the reference ‘White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377-399.’. It provides the flexibility of handling different types of variables at the same time by employing different types of models accordingly. For example, ordinal linear regression is used for imputing continuous variable; logistic regression or discriminant function is used for (ordinal or nominal) categorical variables. For each of the total 56 covariates analysed, there is one imputation model specified. For this clinically orientated manuscript, the full details of this statistical analysis were not provided. However, we have added one sentence in the ‘statistical analysis’ section to explain what specific multiple imputation is used that can deal with both continuous and categorical variables (see page 6).</p>
              <p>‘Multiple imputation by chained equations was used to impute both missing categorical and continuous values.’</p>
              <supplementary-material content-type="local-data" id="pone.0249524.s004">
                <label>Attachment</label>
                <caption>
                  <p>Submitted filename: <named-content content-type="submitted-filename">Rebuttal PLOS one (2)GYHLMK.kjr (1) (3).docx</named-content></p>
                </caption>
                <media xlink:href="pone.0249524.s004.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </body>
          </sub-article>
          <sub-article id="pone.0249524.r003" article-type="aggregated-review-documents">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0249524.r003</article-id>
              <title-group>
                <article-title>Decision Letter 1</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Garcia de Frutos</surname>
                    <given-names>Pablo</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Pablo Garcia de Frutos</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Pablo Garcia de Frutos</copyright-holder>
                <license>
                  <ali:license_ref specific-use="pmc" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj003" ext-link-type="doi" xlink:href="10.1371/journal.pone.0249524" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">22 Mar 2021</named-content>
              </p>
              <p>Manuscript Type: Original article</p>
              <p>Atrial Fibrillation and Comorbidities: Clinical Characteristics and Antithrombotic Treatment in GLORIA-AF</p>
              <p>PONE-D-20-40256R1</p>
              <p>Dear Dr. Kozieł,</p>
              <p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
              <p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
              <p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link ext-link-type="uri" xlink:href="http://www.editorialmanager.com/pone/">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p>
              <p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p>
              <p>Kind regards,</p>
              <p>Pablo Garcia de Frutos</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Additional Editor Comments (optional):</p>
              <p>Reviewers' comments:</p>
              <p>Reviewer's Responses to Questions</p>
              <p>
                <bold>Comments to the Author</bold>
              </p>
              <p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.</p>
              <p>Reviewer #1: All comments have been addressed</p>
              <p>Reviewer #2: All comments have been addressed</p>
              <p>**********</p>
              <p>2. Is the manuscript technically sound, and do the data support the conclusions?</p>
              <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: (No Response)</p>
              <p>**********</p>
              <p>3. Has the statistical analysis been performed appropriately and rigorously? </p>
              <p>Reviewer #1: N/A</p>
              <p>Reviewer #2: (No Response)</p>
              <p>**********</p>
              <p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p>
              <p>The <ext-link ext-link-type="uri" xlink:href="http://www.plosone.org/static/policies.action#sharing">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: (No Response)</p>
              <p>**********</p>
              <p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
              <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: (No Response)</p>
              <p>**********</p>
              <p>6. Review Comments to the Author</p>
              <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
              <p>Reviewer #1: The authors have answered to my questions and suggestions, and I am satisfied with their comments. They have also improved the discussion and tables.</p>
              <p>Reviewer #2: (No Response)</p>
              <p>**********</p>
              <p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link ext-link-type="uri" xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
              <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
              <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link ext-link-type="uri" xlink:href="https://www.plos.org/privacy-policy">Privacy Policy</ext-link>.</p>
              <p>Reviewer #1: No</p>
              <p>Reviewer #2: No</p>
            </body>
          </sub-article>
          <sub-article id="pone.0249524.r004" article-type="editor-report">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0249524.r004</article-id>
              <title-group>
                <article-title>Acceptance letter</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Garcia de Frutos</surname>
                    <given-names>Pablo</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Pablo Garcia de Frutos</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Pablo Garcia de Frutos</copyright-holder>
                <license>
                  <ali:license_ref specific-use="pmc" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj004" ext-link-type="doi" xlink:href="10.1371/journal.pone.0249524" related-article-type="reviewed-article"/>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">5 Apr 2021</named-content>
              </p>
              <p>PONE-D-20-40256R1 </p>
              <p>Atrial Fibrillation and Comorbidities: Clinical Characteristics and Antithrombotic Treatment in GLORIA-AF </p>
              <p>Dear Dr. Kozieł:</p>
              <p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
              <p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p>
              <p>If we can help with anything else, please email us at <email>plosone@plos.org</email>. </p>
              <p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
              <p>Kind regards, </p>
              <p>PLOS ONE Editorial Office Staff</p>
              <p>on behalf of</p>
              <p>Dr. Pablo Garcia de Frutos </p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
            </body>
          </sub-article>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
